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DISSERTATION 
ABSTRACT OF DISSERTATION 
NONINVASIVE NEAR-INFRARED DIFFUSE OPTICAL MONITORING OF 
CEREBRAL HEMODYNAMICS AND AUTOREGULATION 
 
Many cerebral diseases are associated with abnormal cerebral hemodynamics and 
impaired cerebral autoregulation (CA). CA is a mechanism to maintain cerebral blood 
flow (CBF) stable when mean arterial pressure (MAP) fluctuates. Evaluating these 
abnormalities requires direct measurements of cerebral hemodynamics and MAP. Several 
near-infrared diffuse optical instruments have been developed in our laboratory for 
hemodynamic measurements including near-infrared spectroscopy (NIRS), diffuse 
correlation spectroscopy (DCS), hybrid NIRS/DCS, and dual-wavelength DCS flow-
oximeter. We utilized these noninvasive technologies to quantify CBF and cerebral 
oxygenation in different populations under different physiological 
conditions/manipulations. A commercial finger plethysmograph was used to continuously 
monitor MAP. For investigating the impact of obstructive sleep apnea (OSA) on cerebral 
hemodynamics and CA, a portable DCS device was used to monitor relative changes of 
CBF (rCBF) during bilateral thigh cuff occlusion. Compared to healthy controls, smaller 
reductions in rCBF and MAP following cuff deflation were observed in patients with 
OSA, which might result from the impaired vasodilation. However, dynamic CAs 
quantified in time-domain (defined by rCBF drop/MAP drop) were not significantly 
different between the two groups. We also evaluated dynamic CA in frequency-domain, 
i.e., to quantify the phase shifts of low frequency oscillations (LFOs) at 0.1 Hz between 
cerebral hemodynamics and MAP under 3 different physiological conditions (i.e., supine 
resting, head-up tilt (HUT), paced breathing). To capture dynamic LFOs, a hybrid 
NIRS/DCS device was upgraded to achieve faster sampling rate and better signal-to-
noise. We determined the best hemodynamic parameters (i.e., CBF, oxygenated and total 
hemoglobin concentrations) among the measured variables and optimal physiological 
condition (HUT) for detecting LFOs in healthy subjects. Finally, a novel dual-wavelength 
DCS flow-oximeter was developed to monitor cerebral hemodynamics during HUT-
induced vasovagal presyncope (VVS) in healthy subjects. rCBF was found to have the 
best sensitivity for the assessment of VVS among the measured variables and was likely 
the final trigger of VVS. A threshold of ~50% rCBF decline was observed which can 
completely separate subjects with or without presyncope, suggesting its potential role for 
predicting VVS. With further development and applications, NIRS/DCS techniques are 
expected to have significant impacts on the evaluation of cerebral hemodynamics and 
autoregulation. 
Key words: cerebral blood flow (CBF); cerebral oxygenation; cerebral autoregulation 
(CA); near-infrared spectroscopy (NIRS); diffuse correlation spectroscopy (DCS) 
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CHAPTER 1 INTRODUCTION 
1.1 Cerebral Hemodynamics and Cerebral Autoregulation (CA) in Health and 
Disease 
Brain is one of the biggest and most complex organs in human which has a high 
metabolic demand. Maintenance of its normal functions requires the delivery of oxygen 
and glucose and the clearance of metabolic wastes through cerebral blood flow (CBF) 
that accounts for ~14% of the cardiac output (i.e., volume of the blood flow pumped out 
from heart) [1]. To keep CBF stable during blood pressure fluctuations, cerebral 
vasculatures are regulated by means of myogenic, neurogenic, and metabolic 
mechanisms; the so-called cerebral autoregulation (CA) [2, 3]. It is known that capillary 
membrane in cerebral microvasculature is the place where exchanges of nutrition and 
wastes occur. Therefore, adequate CBF and cerebral oxygenation as well as intact CA in 
cerebral microvasculature are critical in maintaining normal brain functions.  
Many people suffering cerebral, cardiovascular or respiratory diseases are usually 
associated with abnormal cerebral microvasculature, cerebral hypoxia, and impaired CA. 
For example, more than 795,000 people in U.S. have stroke every year [4], and tissue 
hypoxia resulting from the ischemic stroke may damage cerebral microvasculature [5] 
and impair CA [6]. About 93,000 patients with carotid artery stenosis underwent carotid 
endarterectomy surgeries in 2009 to prevent stoke [4]. Limited CBF caused by the carotid 
artery stenosis may lead to impaired CA [7, 8]. Another example is obstructive sleep 
apnea (OSA) that affects about 15 million American adults [9, 10]. OSA increases the 
risk of stroke significantly [11] and may result in neurocognitive deficits (e.g., 
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impairments in memory, attention, executive functions and constructional abilities) [12] 
and CA impairment [13].  
CA in healthy subjects works in a relatively large range of mean arterial pressure 
(MAP) fluctuations (60 to 150 mm Hg, see Figure 1.1) [2]. When MAP variation is 
beyond this range, CA is unable to keep CBF stable. Syncope, which is defined by the 
sudden loss of consciousness and posture tone, may occur when CA is completely lost 
[14]. Vasovagal syncope (VVS) is the most common type of syncope [15, 16]. Decreases 
in blood pressure and heart rate resulting from a malfunction of autonomic nervous 
system lead to VVS [17]. Early predication of VVS may help people to avoid VVS and 
consequential accidents. Continuous and simultaneous monitoring of MAP and cerebral 
hemodynamic variables during VVS may provide critical information for predicting VVS 
and determining which variable eventually triggers VVS. 
 
1.2 Quantification of CA 
CA is usually quantified from the relationships between cerebral hemodynamic 
parameters (e.g., CBF and cerebral oxygenation) and blood pressure (e.g., MAP, arterial 
blood pressure (ABP) waveform, systolic blood pressure (SBP), and diastolic blood 
pressure (DBP)) [2, 18, 19]. Evaluation of CA includes static and dynamic methods, 
which are classified by whether the MAP and CBF are stable/static or not at the time of 
measurements [2, 18, 19]. 
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Figure 1.1 Quantification of static CA by simultaneously measuring CBF and MAP 
over a large range of MAP. 
 
Static CA. Classic CA test was performed in a steady state (so called static CA) 
where stepwise changes of MAP in the interval of 30 to 180 mmHg were achieved by a 
pharmacological intervention [18]. CBF was measured for more than 30 seconds at each 
stable MAP via an indicator-dilution method using inert gas, such as N2O, 
85
Kr, or 
133
Xe 
[20-22]. MAP was usually assessed by an intravascular catheter [22]. Figure 1.1 shows a 
typical CA testing result; a constant CBF can be maintained over a large range of 60 to 
150 mmHg. The static method does not address the dynamic process of CA, e.g., whether 
there is a hypoperfusion period between the MAP change and eventual steady state of 
CBF. Evaluation of static CA is limited in clinic due to its invasive nature and sustained 
periods of hypotension and hypertension.  
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Figure 1.2 Quantification of dynamic CA in time-domain (a) and frequency-domain 
(b).  
Vertical dashed lines in panel (b) indicate the peaks of low frequency oscillations at 0.1 
Hz in MAP and cerebral hemodynamics. 
 
Dynamic CA. More recently, researchers have explored a noninvasive method to 
evaluate CA dynamically through noninvasively quantifying cerebral blood flow velocity 
(CBFV) by transcranial Doppler (TCD) ultrasound and MAP by finger plethysmography 
[23, 24]. Analyses of dynamic CA (i.e., the relationship between CBFV and MAP) have 
been done in both time-domain (TD) and frequency-domain (FD) (Figure 1.2).  
In evaluation of TD dynamic CA, an autoregulatory stimulus (e.g., the release of 
bilateral thigh pressure cuffs or head-up tilt (HUT)) is usually used to induce a sudden 
change in MAP. During physiological manipulations, dynamic CA in adjusting CBFV 
during MAP variations is challenged. The cerebral vascular conductance change, 
expressed as CBFV change/MAP change, is often used to determine dynamic CA. A 
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lower cerebral vascular conductance change indicates a better CA since less CBFV 
variation is caused by a unit MAP change. Figure 2.1a shows the analysis of TD dynamic 
CA by monitoring instantaneous responses of MAP and CBFV in major cerebral artery 
(MCA) to an autoregulatory stimulus (i.e., a rapid deflation of bilateral thigh pressure 
cuffs) that results in a sudden MAP drop [23]. 
It has been shown that low frequency oscillations (LFOs) of CBFV and cerebral 
oxygenation at ~0.1 Hz are related to similar intrinsic LFO presented in ABP [7, 25, 26]. 
Although the origin of LFOs in ABP and cerebral hemodynamics remains unclear, 
studies have found that brain exhibits myogenic [27], metabolic [28] and neurogenic [29] 
oscillations in the same low frequency range, which are dominated by sympathetic 
nervous system activity. The myogenic, metabolic, and neurogenic controls are three 
main mechanisms responsible for CA. Thus, evaluation of phase shift (i.e. time interval) 
between the LFOs of MAP and cerebral hemodynamics holds potential for assessing 
dynamic CA in FD [7, 18]. For example, Reinhard et al found a decrease/increase of 
phase lead/lag between LFOs in CBFV/cerebral oxygenation and MAP in patients with 
carotid artery stenosis [7]. According to the report by Hu et al, less phase lead between 
LFOs in CBFV and MAP was found in patients with higher degree carotid artery stenosis 
(i.e., narrow carotid artery) [8]. Figure 1.2b shows the analysis of FD dynamic CA 
through detecting the phase shifts of LFOs in MAP, CBFV, and cerebral oxygenation.  
Current evaluations of dynamic CA in TD and FD are mostly limited to assess CA 
in large arteries (e.g., MCA), which does not always reflect the CA in cerebral 
microvasculature [30]. Furthermore, quantification of the relationships among CBF, 
cerebral oxygenation, and MAP under different physiological conditions/manipulations 
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may determine the most sensitive parameter(s) and robust protocol(s) for assessing 
dynamic CA in cerebral microvasculature. This dissertation focuses on the noninvasive 
evaluation of dynamic CAs in both TD and FD via simultaneously and continuously 
monitoring multiple cerebral hemodynamic parameters and MAP under different 
physiological conditions/manipulations. 
 
1.3 Noninvasive Measurements of Cerebral Blood Flow (CBF) and Cerebral 
Oxygenation 
Various noninvasive techniques have been attempted to monitor CBFV or CBF in 
human including TCD [31], xenon-enhanced computer tomography (XeCT) [32], 
dynamic perfusion computed tomography (PCT) [33], single photon emission computed 
tomography (SPECT) [34], positron emission tomography (PET) [35], arterial spin 
labeled MRI (ASL-MRI) [36], and dynamic susceptibility contrast MRI (DSC-MRI) [37]. 
TCD is widely used, but limited to measure CBFV in large vessels, which may not be 
consistent with CBF in microvasculature [38]. However, many cerebral diseases such as 
stroke and neurocognitive impairment are associated with abnormal microvasculature and 
tissue dysfunction in brain [39, 40]. Moreover, TCD measurements are not applicable for 
approximately 9% of adults due to their having poor acoustic windows [41]. Other 
techniques mentioned above use either endogenous (e.g., ASL-MRI) or exogenous 
tracers (e.g., PET, SPECT, XeCT, PCT, DSC-MRI) to evaluate CBF in microvasculature. 
However, those large imaging modalities are expensive and have relatively low temporal 
resolutions and poor mobility.  
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Noninvasive techniques for measuring cerebral oxygenation in human include 
blood oxygen level dependent MRI (BOLD-MRI) [42] and near-infrared spectroscopy 
(NIRS) tissue oximeter [43]. Both techniques are sensitive to cerebral oxygenation in 
microvasculature. Again, although BOLD-MRI can image cerebral hemodynamics with 
high spatial resolution, the high cost, low temporal resolution, and poor mobility limit its 
frequent use in clinic. By contrast, the inexpensive, portable, and easy-to-use NIRS 
allows for fast and longitudinal measurements at the bedside of clinic, although its spatial 
resolution is relatively low. 
Since cerebral hemodynamic parameters (e.g., CBF and cerebral oxygenation) are 
usually coupled and interactive, it is desirable to simultaneously measure multiple 
hemodynamic variables and investigate their complex relationships. Combination 
measurements have been reported previously using NIRS, PET [44], ASL-MRI [45], and 
BOLD-MRI [46]. Nevertheless, inexpensive, portable, fast, and easy-to-use devices are 
needed for continuous and simultaneous measurements of both CBF and cerebral 
oxygenation at the bedside of clinic. 
 
1.4 Near-infrared Spectroscopy (NIRS) 
NIRS provides a noninvasive, rapid, portable, and low-cost alternative to monitor 
tissue oxygenation (including oxy-hemoglobin concentration ([HbO2]), deoxy-
hemoglobin concentration ([Hb]), total hemoglobin concentration (THC), blood oxygen 
saturation (StO2)), which makes it ideal for research and clinical uses [47-50].  
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Figure 1.3 Absorption spectra of hemoglobin and water.  
Tissue absorption coefficients (μa) are shown as a function of wavelength (λ). The 
oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb), and water (H2O) are 
major absorbers in biological tissues. Within the NIR spectral window (650 to 900 nm), 
light can penetrate tissues deeply due to the relatively low tissue absorption. 
 
NIRS uses NIR light in the range of 650 to 900 nm where tissue absorption is 
relatively low (Figure 1.3). Therefore, NIR light can penetrate deep tissues up to several 
centimeters. Absorption and scattering occur when NIR photons interact with the tissue 
absorbers (e.g., HbO2, Hb, H2O) and scatterers (e.g., cell membranes, organelles, nuclei). 
Here HbO2 represents the hemoglobin bound to four oxygen molecules, Hb represents the 
hemoglobin without binding of O2 [51, 52], and H2O represents water. NIR light 
transported in tissues is dominated by scattering events rather than absorption and can be 
approximated as a diffusive process (Chapter 2.1). Tissue optical properties are 
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characterized by absorption and reduced scattering coefficients, represented by μa and μs’ 
(cm
-1
), respectively. 
 
Figure 1.4 Three types of NIRS tissue oximeters. 
Panel (a) shows a continuous-wave (CW) NIRS, in which attenuated intensity of 
continuous illumination light is monitored. Panel (b) represents a frequency-domain (FD) 
NIRS, in which incident light is modulated and the amplitude attenuation and phase shifts 
due to tissue absorption and scattering are detected. Here, I, IDC, and IAC represent light 
intensity, averaged intensity, and peak-to-peak intensity, respectively. Φ represents the 
phase of modulated light. Panel (c) demonstrates a time-domain (TD) NIRS, in which an 
impulse of light is emitted into the tissue, and the intensity change with respect to time is 
detected. 
 
Three types of NIRS devices are currently used for diffuse optical measurements, 
which are classified based on the types of light sources utilized [53]. The continuous-
wave (CW) system is the simplest approach which uses a CW light source (Figure 1.4a). 
The photodetector measures the attenuated light intensity caused by tissue absorption and 
scattering. The FD system utilizes an amplitude-modulated light source at a radio-
frequency range (10 to 1000 MHz) and measures the light intensity reductions including 
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a DC component (average intensity) and an AC component (peak-to-peak intensity) as 
well as phase shift relative to the incident light. The TD system employs a very short 
pulse source (~100 ps) and detects the temporal broaden and delay of the output pulse 
[54]. 
Among the three paradigms, CW system is simplest and least expensive [55], but 
it provides only information of relative changes in [Hb], [HbO2], and THC (i.e., Δ[Hb], 
Δ[HbO2], and ΔTHC) [56]. FD technique enables quantification of absolute values of μa 
and μs’, thus providing absolute assessments of [Hb], [HbO2], THC, and StO2. TD 
measurement provides more information than CW and FD systems (e.g., tissue properties 
at different depths) with the cost of expensive and complex instrumentation. 
 
1.5 Near-infrared (NIR) Diffuse Correlation Spectroscopy (DCS) 
DCS is a relatively new technique for CBF measurements [6, 38, 57-64]. Similar 
to NIRS (Figure 1.4), DCS uses NIR light to penetrate deep tissues.  However, the light 
source used in DCS is a CW laser with long coherence length (> 5 meter) and the 
detector used is the very sensitive single-photon-counting avalanche photodetector 
(APD). DCS detector detects light intensity fluctuations at a single speckle area on the 
tissue surface using a single-mode fiber connected to the APD. Interactions between 
photons and moving scatterers (primarily red blood cells in microvasculature) result in 
light intensity fluctuations at a single speckle area. Through quantification of the time 
scale of light intensity fluctuation, DCS generates a blood flow index (BFI) which is 
related to the motion of red blood cells (Chapter 2.3). Relative change of blood flow 
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(rBF) is determined subsequently by normalizing time-course BFI data to its baseline 
value before the physiological change.  
DCS for rBF measurements has been extensively validated against other 
techniques in various organs/tissues, including TCD in premature infant brain [65, 66], 
power spectral Doppler ultrasound in murine tumors [67], laser Doppler flowmetry in rat 
and mouse brains [68, 69], fluorescent microsphere measurement of CBF in piglet brain 
[70], ASL-MRI in human brain and muscle [71, 72], and Xenon computed tomography in 
traumatic brain [73]. 
 
1.6 Current Study Limitations 
Quantification of dynamic CA requires simultaneous measurements of MAP and 
cerebral hemodynamic variables including CBF and cerebral oxygenation. Although 
many techniques are capable of measuring cerebral hemodynamics, current studies of 
dynamic CA are mostly limited to evaluate CA in large cerebral vessel (e.g., MCA) using 
CBFV measured by TCD [13]. It is known that abnormal microvasculature and tissue 
hypoxia have been observed in cerebral diseases associated with impaired CA [74, 75]. 
Although researchers have attempted to assess dynamic CA in microvasculature through 
measuring cerebral tissue oxygenation by NIRS [7], cerebral oxygenation changes may 
not be consistent with CBF variations. In addition, previous studies usually evaluate 
dynamic CA from one single hemodynamic parameter (e.g., CBFV or cerebral 
oxygenation). However, cerebral hemodynamic parameters are usually interactive. 
Therefore, concurrent measurements of multiple cerebral hemodynamic parameters are 
critical for the evaluation of CA.  
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Our strategy to overcome above limitations is to develop various noninvasive NIR 
diffuse optical instruments for simultaneous measurements of multiple cerebral 
hemodynamic parameters. The instruments that we have developed and/or built include a 
portable single-wavelength DCS flowmeter, a portable dual-wavelength DCS flow-
oximeter, and a large hybrid NIRS/DCS device. The custom-made DCS flowmeter can 
directly measure CBF in the microvasculature of frontal cortex. Both custom-designed 
hybrid NIRS/DCS and DCS flow-oximeter can simultaneously measure variations in 
CBF and cerebral oxygenation. Although the hybrid NIRS/DCS provides absolute 
measurements of cerebral oxygenation, it is more expensive and larger than the portable 
DCS flow-oximeter. We then applied these instruments with different experimental 
protocols/stimuli (e.g., bilateral thigh pressure cuff occlusion or HUT) to evaluate 
dynamic CA in different populations (e.g., patients with OSA or healthy controls). The 
ultimate goal is to find the most sensitive cerebral hemodynamic parameters and most 
robust protocols for evaluating cerebral hemodynamics and dynamic CA. 
This thesis is organized with the following chapters. Chapter 2 introduces the 
theory and instrumentation of NIRS and DCS technologies. Chapter 3 describes a study 
using a DCS flowmeter to evaluate TD dynamic CA in patients with OSA. Chapter 4 
demonstrates the feasibility of evaluating FD dynamic CA using the phase shifts of LFOs 
between the MAP and cerebral hemodynamics (CBF and cerebral oxygenation) measured 
by an upgraded hybrid NIRS/DCS instrument. Chapter 5 depicts diffuse optical 
monitoring of cerebral hemodynamics during VVS in healthy subjects using a novel dual-
wavelength DCS flow-oximeter. Finally, Chapter 6 summarizes the novelties of the 
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present studies and my contributions to the field, discusses study limitations, and 
eventually points out future study directions.  
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CHAPTER 2 THEORY AND INSTRUMENTATION OF NIR DIFFUSE 
OPTICAL TECHNILOGIES  
Several NIR diffuse optical instruments have been recently developed in our 
laboratory and used in the studies covered by this dissertation, including a single-
wavelength DCS flowmeter, a hybrid NIRS/DCS device which integrates a commercial 
FD NIRS oximeter (Imagent, ISS Inc., IL, USA) and a custom-made CW DCS flowmeter 
[76], and a novel custom-designed dual-wavelength DCS flow-oximeter [77]. The single-
wavelength DCS flowmeter measures only CBF while both hybrid NIRS/DCS and dual-
wavelength DCS flow-oximeter are able to monitor both CBF and cerebral oxygenation. 
The hybrid NIRS/DCS device can quantify absolute values of cerebral oxygenation 
including [HbO2], [Hb], THC, and StO2. DCS flow-oximeter can detect relative changes 
of cerebral oxygenation including Δ[HbO2], Δ[Hb], and ΔTHC. The dimensions/costs of 
the single-wavelength DCS flowmeter and dual-wavelength DCS flow-oximeter are 
similar, but much smaller/less than the hybrid NIRS/DCS.  
 
2.1 Basics of NIR Diffuse Optical Techniques 
When using NIR diffuse optical techniques to detect cerebral oxygenation or CBF, 
a pair of source and detector fibers is usually placed on the tissue surface with a distance 
of a few millimeters to centimeters. NIR light generated by a laser transmits into tissues 
through the source fiber (Figure 2.1). Based on the diffusion theory, photons transported 
in highly scattered biological tissues can be treated as a diffusive process [78, 79]. More 
specifically, some photons may be absorbed by tissue absorbers including hemoglobin, 
and water while more photons are scattered by tissue scatterers including cell membranes, 
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organelles, and nuclei. Only a few photons can be scattered back to the tissue surface and 
detected by the photodetector through the detector fiber. The penetration depth of NIR 
light in biological tissues is approximately half of the source-detector (S-D) separation (ρ) 
[80, 81]. NIRS measures the amplitude reductions and phase shifts (for a FD system) at 
multiple wavelengths to extract tissue blood oxygenation information [80, 81]. DCS 
blood flow measurement is accomplished by monitoring light intensity fluctuations 
(caused by the motion of red blood cells) at a single speckle area on tissue surface using a 
single-mode detection fiber [82-84]. 
 
Figure 2.1 Photons transported in tissue experience absorption and scattering 
events. 
The source and detector fibers are placed on the tissue surface at a distance ρ. Grey and 
red dots represent tissue absorbers (e.g., hemoglobins and water) and scatterers (e.g., cell 
membranes, organelles, and nuclei), respectively. The green arrows represent the moving 
directions of moving scatterers (primarily red blood cells). The solid and dashed blue 
lines indicate potential paths of the detected photons. The dashed black lines indicate the 
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potential paths of the photons absorbed by tissue absorbers. The pink banana shadow area 
indicates the average path of the detected photons. 
 
2.2 NIRS for Cerebral Blood Oxygenation Measurement 
Different physical models have been used to describe photon transportation in 
biological tissues, including a complex photon diffusion equation [78, 84] and a simple 
modified Beer-Lambert law (MBLL) [85]. One can extract either absolute μa using the 
photon diffusion equation or relative change of μa (Δμa) using the MBLL. The measured 
μa or Δμa is then decomposed into the absorption contributions from different tissue 
chromophores:  
 μa(λ) = ∑          (2.1)  
 Δμa(λ) = ∑           (2.2)  
Here       is the known molar extinction coefficient at wavelength ( ) for the i
th
 
chromophore.    is the concentration of the i
th
 chromophore and    .is the change of   . 
The sum is over tissue chromophores which are mainly HbO2 and Hb. Water (H2O) 
absorption usually does not change much and is thus fixed based on the literature [86]. 
Two unknown chromophore’s concentrations (or concentration changes) require the 
measurements at minimum two wavelengths. Using measured absolute concentrations of 
HbO2 and Hb, one can further calculate THC and StO2:  
 THC = [HbO2] + [Hb] (2.3)  
 StO2 = [HbO2]/THC*100% (2.4)  
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2.2.1 Theory of Continuous-wave (CW) NIRS 
In CW NIRS, MBLL is often used to describe the change in light intensity due to 
Δμa. The MBLL is written as: 
 ΔOD(λ) = log[IB(λ)/IT(λ)] = Δμa(λ) * photon pathlength (2.5)  
where ΔOD(λ) is the change in optical density measured at a given wavelength (λ), and 
IB(λ) and IT(λ) are the measured baseline and transient light intensities, respectively. 
Δμa(λ) results from the concentration changes in absorbing species (mainly [HbO2] and 
[Hb]), and thus can be written as:  
 Δμa(λ) =      (λ)Δ[HbO2] +        Δ[Hb] (2.6)  
 
Figure 2.2 Wavelength-dependent molar extinction coefficients (cm
-1
∙M
-1
) of 
oxygenated hemoglobin (HbO2) and deoxygenated hemoglobin (Hb) in NIR window 
of 650 to 900 nm. 
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Here,         and        are molar extinction coefficients of HbO2 and Hb at 
wavelength λ (Figure 2.2). Due to scattering effects, the pathlengths of detected photons 
are usually longer than the S-D separation ρ (Figure 2.1). The increased distance that 
light travels from the source to the detector can be determined by a differential pathlength 
factor (DPF): 
                             (2.7)  
where         ,       , and DPF(λ) can be found from the literature [87].   
Using the measured light intensity changes at two wavelengths (λ1 and λ2) and 
Equations 2.5 to 2.7, one can derive Δ[HbO2] and Δ[Hb] in a unit of µM relative to their 
baselines (assigned to be 0):  
 [
   [            ⁄ ]
   [            ⁄ ]
]  [
                
                
] [
 [    ]
 [  ]
]        (2.8)  
Here µM represents µmol/L and ΔTHC can be calculated by the sum of Δ[HbO2] 
and Δ[Hb]. 
 
2.2.2 Instrumentation of CW NIRS 
Figure 2.3 shows the schematics of a typical CW NIRS system. A transistor–
transistor logic (TTL) signal is used to switch the two NIR sources/wavelengths 
alternately; only one source is on at a time. The photodetector senses the light intensity 
change which is associated with Δμa. We can then extract Δ[HbO2], Δ[Hb], and ΔTHC 
from the measured Δμa at the two wavelengths. The optical probe consists of an optical 
detector and two light sources. 
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Figure 2.3 Schematics of a typical CW NIRS system. 
 
2.2.3 Theory of Frequency-domain (FD) NIRS 
Photon diffusion equation. Photon transportation in biological tissues can be 
approximately treated as a diffusing process because scattering events dominate photon 
propagation inside the tissue [78, 79]. μs’ is often much larger (>10 folds) than μa in 
biological tissues. If one tracks the trajectory of each photon inside the tissue using 
Monte Carlo simulation, a random walking pattern would be observed. Photon 
propagation inside tissue as a diffusive process can be described by the photon diffusion 
equation [78, 88]. Specifically, the measured photon fluence rate Φ(r,t) (photons/[s∙cm
2
]) 
obeys the time-dependent photon diffusion equation in a homogeneous medium [78, 84, 
88, 89]: 
                             
       
  
 (2.9)  
Here v (cm/s) is the speed of light in medium and D = v/3(μa + μs’) (cm
2
/s) is the 
photon diffusion coefficient. S(r, t) (photons/[s∙cm
3
]) is an isotropic source term which 
gives the number of photons emitted at position r and time t per unit volume per unit 
time. The right hand side (RHS) of Equation 2.9 shows the changing rate of photons 
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within a sample volume. This rate equals the number of photons scattered into the volume 
per unit time from its surroundings (the first term on the left hand side (LHS) of Equation 
2.9), minus the number of photons absorbed per unit time within the volume (the second 
term on the LHS), plus the number of photons emitted per unit time from any sources in 
the volume (the third term on the LHS) [84]. 
 In case of FD NIRS, a frequency modulated source is used. Then the source term 
S(r,t) and photon fluence rate        are written as 
        (        
    )     (2.10)  
                      
            (2.11)  
where SDC and SAC are DC and AC components of source power indicating the number of 
photons emitted in unit time.   is the modulation frequency (e.g., 110 MHz for the 
Imagent device).   represents the phase difference between the source and detected lights. 
Substituting the S(r,t) and       in Equation 2.9 with those in Equations 2.10 and 2.11, 
we can get the following two equations for the DC and AC components [76]:  
                                (2.12)  
 
          
                      
                 
        
           
            
(2.13)  
Equations 2.12 and 2.13 can be further simplified as [76]: 
     
   
 
         
        
 
 (2.14)  
 [   
      
 
]        
     
          
 
 (2.15)  
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Homogeneous solutions of photon diffusion equation in infinite tissue 
geometry. Analytical solutions of    ,    , and   for homogeneous medium with 
infinite geometry (see Figure 2.4a) are derived in Appendix I. Linear relations exist 
between   [        ],   [        ]  or      and   [76]: 
    [        ]    (
   
 
)
  ⁄
   (
   
   
) (2.16)  
   [        ]    (
   
  
)
  ⁄
[        ⁄   ]
  ⁄
   (
   
   
) (2.17)  
       (
   
  
)
  ⁄
[        ⁄   ]
  ⁄
 (2.18)  
where x is defined as      . The slopes (SLAC, SLDC, SLφ) of these linear regression can 
be fitted from the measured   [        ],   [        ], and      at different   (e.g., 
  = 2.0, 2.5, 3.0, and 3.5 cm for the Imagent device, see Chapter 2.2.4). Meanwhile, these 
slopes are functions of μa and μs’ (note that D =            ⁄ ) according to the first 
terms on the RHS of Equations 2.16 to 2.18 [76].  
       (
   
 
)
  ⁄
 (2.19)  
       (
   
  
)
  ⁄
[        ⁄   ]
  ⁄
 (2.20)  
     (
   
  
)
  ⁄
[        ⁄   ]
  ⁄
 (2.21)  
Therefore, μa and μs’ can be extracted from the measured     ,     , and    , 
using Equations 2.19 to 2.21. Since there are three equations and only two unknowns, any 
two slopes can be used. In practice, however, the small difference between      and 
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     observed in tissues prevents the use of this pair.      and     pair is often used, 
because      is less influenced by room light. Using      and    , we have [76] 
    
 
  
(
   
    
 
    
   
) (2.22)  
   
  
 (   
      
 )
   
    (2.23)  
Compared to the CW NIRS measurements, absolute values of μa and μs’ at 
different wavelengths quantified by FD NIRS allow us to extract absolute values of 
cerebral oxygenation (i.e., [HbO2], [Hb], THC, StO2) using Equations 2.1, 2.3, and 2.4. 
 
Figure 2.4 Illustration of infinite (a) and semi-infinite (b) geometries to solve the 
photon diffusion equation (see also Appendix I). 
 
Homogeneous solutions in semi-infinite geometry. The infinite geometry is 
often not practical for in vivo tissue measurements. The solutions derived in semi-infinite 
geometry of homogenous medium (Figure 2.4b) is usually used for noninvasive real 
tissue measurements. A collimated light source is usually approximated as an isotropic 
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source located at z = z0 = 1/μs’ inside the medium, as the direction of photon movement 
becomes random after its first scattering event [90]. 
The physical boundary condition at the interface between the scattering (e.g., 
biological tissues) and non-scattering (e.g., air) media is that there are no incoming 
photons at the boundary. Apparently, a mismatch of the refraction index at the interface 
of the strongly scattering medium (nin) and the outside non-scattering medium (nout) 
accounts for an inwardly directed component of the photon flux (Jin) at the boundary. An 
extrapolated zero boundary (-zb) in the non-scattering medium where Jin(z = -zb) = 0, can 
be determined from the zero partial flux boundary condition [91-93]: 
        
 
 
     
 
  
      
      
     
  ̂
   (2.24)  
Here, Reff = -1.44n
-2 
+ 0.71n
-1 
+ 0.668 + 0.064n is the effective reflection 
coefficient determined by the ratio of refraction indices inside and outside the scattering 
medium, n = nin/nout ≃ 1.33 [90], and  ̂ is the vector normal to the boundary. Then -zb = 
 
 
   
      
      
 is extrapolated from Equation 2.24. For semi-infinite homogeneous 
geometry, the extrapolated zero boundary condition is satisfied by placing a negative 
isotropic imaging source located at z = -(z0 + 2zb) (Figure 2.4b) [84]. 
The analytical solutions of   ,   , and   in semi-infinite geometry are derived 
in Appendix I.    and   
  can be fitted iteratively from the analytical solutions although 
iterations are often time consuming. Therefore, faster approximate solutions defined by 
the following equations are often employed [94]: 
   [        
 ]            (2.25)  
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   [        
 ]            (2.26)  
              (2.27)  
where     ,     , and     are defined in Equations 2.19 to 2.21 and can be fitted from 
the measured   [        
 ],   [        
 ], and      at different  . KDC, KAC, and 
Kφ are ρ-independent functions.    and   
  can then be calculated using Equations 2.22 
and 2.23 [94]. Finally, [HbO2], [Hb], THC, and StO2 can be calculated from the measured 
   at different wavelengths (e.g., 690 and 830 nm for the Imagent device, see Chapter 
2.2.4). 
 
2.2.4 Instrumentation of FD NIRS 
 
Figure 2.5 Photo (a) and schematics (b) of a commercial FD NIRS (Imagent, Iss Inc., 
IL, USA) and picture of a fiber-optic probe (c).  
 
In this study a commercial FD NIRS (Imagent, Iss Inc., IL, USA) was used 
(Figure 2.5) which contains two banks of multiplexed sources (each bank has eight laser 
diodes at the same wavelength) and two photomultipliers (PMT) detectors. The two 
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detectors work in parallel and each serves its own multi-distance probe (ρ = 2.0, 2.5, 3.0, 
and 3.5 cm). The fiber-optic probe is optically coupled to laser-diode sources by multi-
mode fibers (core diameter = 400 um). A large fiber bundle (core diameter = 2.5 mm) 
connected to the PMT is used to detect the reflected light from the tissue. Laser-emitted 
lights at 690 and 830 nm are modulated at 110 MHz and multiplexed so that only one 
source in each bank is on at a time.   ,   , and   are measured and used to calculate 
   and   
  (at both wavelengths) and hemoglobin concentration values. Typically, the 
measurement time for each cycle covering all source-detector pairs and wavelengths is 
150 ms. Data from several cycles can be averaged to improve signal-to-noise ratio (SNR) 
when high sampling rate is not necessary. 
 
2.3 DCS for CBF Measurement 
Similar to NIRS, DCS also utilizes NIR light to penetrate deep tissues. However, 
NIRS monitors tissue blood oxygenation variations through quantifying the relatively 
slow changes in light intensity level and phase (for FD system) due to the slow changes 
in tissue absorption and scattering, whereas DCS monitors directly the motion of moving 
scatterers (mainly red blood cells) in tissue through quantifying the fast temporal 
fluctuations in light intensity. Therefore, DCS is considered as a “dynamic NIR technique” 
as opposed to the “static NIRS”.  
 
 
26 
2.3.1 Theory of DCS 
DCS, also known as diffusing wave spectroscopy (DWS) [95, 96], originated 
from the single dynamic light scattering (DLS) technique. DLS has been widely applied 
to study particle suspension properties (e.g., particle size and shape) in optically thin 
physical systems. Later, Boas et al [82-84] derived a correlation diffusion equation from 
the correlation transport theory [97, 98], which described the propagation of 
unnormalized electric field temporal autocorrelation function in highly scattered turbid 
medium. Appendix II describes the derivation of correlation diffusion equation from 
both single scattering and multiple scattering events.  
 In most experiments, the normalized temporal intensity autocorrelation function, 
        〈               〉 〈      〉
 ⁄ , is calculated from the detected intensity 
fluctuations of scattered light. Here r is the location vector which denotes a general vector 
from a source to a point of detection, and   represents the delay time of autocorrelation 
function.         is related to the normalized electric field temporal autocorrelation 
function,      , through the Siegert relationship [99]:  
                     
  (2.28)  
where   depends on laser stability and coherence length and the number of detected 
speckles, which can be determined experimentally from the measured         via 
           . The unnormalized electric field temporal autocorrelation is defined by 
         =                                (2.29)  
The motions of moving scatterers in biological tissue (mainly red blood cells) 
contribute to the exponential decay of G1. The transport of G1 results in the following 
correlation diffusion equation in homogeneous medium for CW light source [82-84]. 
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 [   (     
    
    
 〈      〉)]         
       
 
 (2.30)  
Here D ≃ v/3  
 .        is the CW source term, where S0 is a constant. 〈  
    〉 
is the mean-square displacement of moving scatterers in delay time τ. The scatterer 
movement combining with photon absorption (i.e.,      
    
    
 〈      〉) gives an 
effective “absorption” term for the attenuation of G1 as it travels through the medium. The 
formal similarity of Equation 2.14 (i.e.,     
   
 
         
        
 
) and Equation 
2.30 suggest that their solutions are also formally similar. In a semi-infinite homogeneous 
medium (Figure 2.4b), analytical solutions of         and         can be obtained [84]: 
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Here   is the S-D separation,    √      ,     √             (Figure 
2.4b),    
 
   
 ,    
 
   
 
      
      
, Reff = -1.44n
-2 
+ 0.71n
-1 
+ 0.668 + 0.064n, n = nin/nout 
(e.g., n = 1.33/1 for biological tissue/air interface) is the same as the previous definition 
in Chapter 2.2.3, and           
    
    
 〈      〉, where        ⁄ . Meanwhile, 
the measured                 can be converted from the measured         using the 
Siegert Relation [99] (Equation 2.28). 
 To adapt the correlation diffusion equation for the use in biological tissues, a 
unitless factor α (ranging from 0 to 1) is introduced to represent the ratio of light 
scattering events resulted from “moving” scatterers (e.g., red blood cells) to the total 
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scatterers, since some of the scatterers in tissue are “static” (e.g., organelles, 
mitochondria, and nuclei). The factor α is included as a pre-fix to 〈      〉  (i.e., 
 〈      〉) to indicate the mean square displacement of “moving” scatterers in biological 
tissues. Then         depends on           
    
    
  〈      〉  and thus is a 
function of tissue optical properties (   and   
 ) and the mean-square-displacement of the 
“moving” scatterers   〈      〉 . By assuming from literature or measuring the values of 
   and   
  by NIRS,         is solely determined by the term of  〈  
    〉. 
For the case of diffusive motion,  〈      〉       , where    is the effective 
Brownian diffusion coefficient of tissue scatterers, and is distinct from the well-known 
thermal Brownian diffusion coefficient [100]. By varying     in the                   
and fitting it to                , one can extract    . Practically, we have observed that 
the diffusion model, i.e. 〈      〉      , fits the autocorrelation curves rather well than 
the random flow model over a broad range of tissue types, ranging from mouse brain [69] 
and mouse muscle [101, 102], adult human skeletal muscle [77, 103-106], adult human 
tumors [107], and adult brain [25, 63]. The reason for the Brownian-motion like 
correlation curve is still not apparent and more investigations are needed to understand its 
underlying mechanism. Nevertheless, DCS tissue blood flow measurements have been 
adopted by many researchers in biomedical field [25, 30, 60, 61, 81, 108-110]. 
Although the unit of     (cm
2
/s) is different from the traditional blood perfusion 
unit [ml/min/100 g], relative changes in this blood flow index (            ) have 
been found to correlate quite well with other blood flow measurement modalities [65-73] 
(see also Chapter 1.5), where      is the baseline flow value measured before the 
physiological change.  
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2.3.2 Instrumentation of DCS 
 
Figure 2.6 A typical 4-channel DCS device (a) and a diagram for DCS data 
processing (b). 
 
Figure 2.6a shows a typical 4-channel DCS device consisting of a CW long-
coherence (> 5 m) laser at 785 nm (100 mw, CrystaLaser Inc., NV, USA), 4 single-
photon-counting avalanche photodiodes (APDs) (e.g., Perkin Elmer Inc., Canada), and an 
autocorrelator board (Correlator.com, NJ, USA). The laser diode shines the light through 
a multi-mode source fiber (diameter = 200 µm) into the tissue (Figure 2.6b). In a single 
speckle area on the tissue surface, the temporal light intensity variations caused by the 
moving scatterers (primarily red blood cells in the microvasculature) are detected by a 
single-mode fiber (diameter = 5 µm) connected to one of the APDs. The output of the 
APD is sent to an autocorrelator board for calculating the normalized light intensity 
temporal autocorrelation function (g2), which is then converted to the normalized electric 
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field temporal autocorrelation function (g1) for the quantification of αDb (see the data 
processing diagram shown in Figure 2.6b).  
A fiber-optic probe is usually made using source and detector fibers confined by a 
custom-designed soft foam pad (Figure 2.6a). The S-D separation is selected according to 
the tissue depth probed (e.g., ρ = 2.5 cm for adult brain measurements [25, 38, 61, 63, 64, 
68, 108], ρ = 0.6 cm for mouse skeletal muscle measurements [69, 111]). The sampling 
rate of DCS also varies according to specific applications. For example, we have used a 
fast sampling rate of 2 Hz for quantifying LFOs in CBF [25] and a low sampling rate of 
0.33 Hz for measuring rBF in calf muscle during thigh cuff occlusion [77]. There is 
generally a tradeoff between the sampling rate and SNR. The faster the sampling rate is, 
the less the light intensity detected associated with a lower SNR. In addition, both spatial 
and temporal averaging can improve the SNR.  
 
2.4 Hybrid NIRS/DCS Instruments 
As mentioned in Chapter 1, there is a critical need for simultaneous measurements 
of CBF and cerebral oxygenation. Previously, Yodh’s group at the University of 
Pennsylvania combined a custom-made homodyne FD NIRS instrument with a DCS 
device for simultaneous measurements of tissue blood flow and oxygenation [57, 110, 
112]. However, the homodyne detection system used for NIRS measurements had lower 
SNR than heterodyne FD NIR systems (e.g., Imagent, ISS Inc. IL, USA). Our group has 
initially attempted combination of the heterodyne FD Imagent (ISS Inc.) and DCS device 
(Figure 2.7) to improve the SNR [77].  
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Figure 2.7 A typical hybrid NIRS/DCS instrument consisting of a commercial tissue 
oximeter (Imagent) and a custom-made 4-channel DCS flowmeter. 
 
First generation hybrid NIRS/DCS instrument. Figure 2.7 shows the picture 
and diagram of our first generation hybrid Imagent/DCS instrument. Computer-controlled 
TTL signals were used to control the Imagent and DCS devices working sequentially. 
Acquisition times for Imagent and DCS measurements can be varied based on the needs 
for different studies. A 50 ms delay between the transition of Imagent and DCS 
measurements was set to avoid the potential cross-measurement interference. The design 
of the hybrid fiber-optic probe was based on the commercial Imagent probe (Figure 2.8). 
DCS source and detector fibers were housed inside the Imagent probe. The optical fibers 
for the DCS measurement were arranged in a particular pattern (Figure 2.8) for reducing 
the interference between DCS and NIRS measurements [77]. The probe regions and 
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penetration depths for CBF and cerebral oxygenation measurements are slightly different 
due to this specific probe design. Using this hybrid system, we have successfully 
quantified blood flow and blood oxygenation in brain [113], skeletal muscle [77, 103, 
104, 114], head and neck tumor [107]. Since then [77], several other groups have also 
built similar hybrid Imagent/DCS systems for their studies [64, 66, 115]. 
 
Figure 2.8 A typical fiber-optic probe used in the hybrid NIRS/DCS device. 
 
Upgraded hybrid NIRS/DCS instrument. High sampling rate and SNR of 
optical measurements are needed to capture instantaneous changes in cerebral 
hemodynamics (e.g., LFO signals) for evaluation of dynamic CA (Chapter 4). For these 
purposes, an upgraded hybrid NIRS/DCS instrument was designed and built (Figure 2.9). 
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Instead of using a continuous-mode autocorrelator board in the first generation hybrid 
instrument (Figure 2.7), a new autocorrelator board capable of working in both 
continuous and burst modes (Correlator.com, NJ, USA) was adopted for DCS 
measurements. The autocorrelator communicated with DCS control panel (a laptop 
computer) through a USB port (Figure 2.9). The least time (6.5 ms) to obtain a 
correlation function curve using the burst mode was much shorter than that (104 ms) 
using the continuous mode. As a result, the burst mode increased the sampling rate by 16 
times compared to the continuous mode. In addition, working in the burst mode the 
autocorrelator started only once at the beginning of data collection (Figure 10a). By 
contrast, the autocorrelator working in continuous mode restarted repeatedly for the 
collection of each correlation curve (Figure 10b). Frequent rebooting of the autocorrelator 
under continuous mode consumed time, thus significantly reducing the efficiency of data 
collection. Furthermore, more DCS detectors (16 detection channels) were added to the 
upgraded hybrid instrument, which allowed for spatial averaging of DCS signals to 
improve the SNR of DCS measurements (Chapter 4). Theoretically, spatial averaging 
signals from N detection channels can increase the SNR of CBF measurements by √  
times.  
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Figure 2.9 Photo (a) and diagram (b) of an upgraded hybrid NIRS/DCS instrument. 
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Figure 2.10 Flow charts of burst (a) and continuous (b) modes of an autocorrelator 
board. 
 
Two identical hybrid fiber-optic probes (Figure 2.9b) were built for detecting both 
CBF and cerebral oxygenation changes in the left and right hemispheres of brain, 
respectively. For CBF measurements, each probe contained one DCS source fiber 
(diameter = 200 µm) connected to a laser diode at 830 nm and 8 single-mode fibers (core 
diameter = 5.6 µm) that were tightly bundled for detecting light intensity fluctuations at a 
small area (~0.16 mm
2
). Signals from the 8 APDs were averaged to increase the SNR of 
DCS measurements [59]. Tissue heterogeneity within this small detection area can be 
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ignored. The S-D separation of DCS fibers was set to 2.5 cm, which allowed for the 
detection of CBF in adult prefrontal cortex [38, 61, 63, 64, 71, 108]. For cerebral 
oxygenation measurements, each probe contained 8 Imagent source fibers (4 per 
wavelength) connected to laser diodes and one detection fiber coupled to one PMT. The 
source fibers (diameter = 400 µm) were arranged at distances of 2.0, 2.5, 3.0, 3.5 cm 
from the detector fiber (diameter = 2.5 mm).  
To avoid the light interference between flow and oxygenation measurements, the 
lasers for DCS and Imagent measurements were turned on sequentially in each probe. 
However, bilateral measurements in the two hemispheres were conducted simultaneously 
since the light emitted from one probe did not affect the detectors in another probe. The 
sampling time for one frame of cerebral hemodynamic data was ~500 ms (equivalent to a 
sampling rate fs = 2 Hz) which included ~150 ms for DCS measurement, ~250 ms for 
Imagent measurement, and ~100 ms for switching between the two measurements. The 
data acquisition and communication between the two devices (through digital I/O lines) 
were automatically controlled by custom-designed software installed on the two control 
panels (computers) for DCS and Imagent, respectively [77, 81, 103]. 
 
2.5 Dual-wavelength DCS Flow-oximeter 
Although the hybrid NIRS/DCS systems can effectively quantify both CBF and 
cerebral oxygenation, it is relative expensive, large and complicated to build and operate. 
In addition, the probing regions of CBF and cerebral oxygenation measurements are 
slightly different duo to the location discrepancy of Imagent and DCS fibers (Figure 2.8). 
A portable dual-wavelength DCS flow-oximeter was recently developed in our 
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laboratory, which can simultaneously measure the relative changes in CBF and cerebral 
oxygenation from the same region of tissues [77].  
 
Figure 2.11 Photo (a), fiber-optic probe (b), and diagram (c) of a dual-wavelength 
DCS flow-oximeter. 
 
Figure 2.11 shows a dual-wavelength 4-channel DCS flow-oximeter. Basically, 
we added another long-coherence CW laser at 854 nm to the previous single-wavelength 
(785 nm) DCS system. The two lasers were switched on and off alternately by TTL 
signals controlled automatically by DCS control panel. Similarly to CW NIRS, we can 
extract relative changes of tissue blood oxygenation (i.e., Δ[HbO2], Δ[Hb], ΔTHC) via 
measuring light intensity changes at the two wavelengths (Chapter 2.2.1). The dual-
wavelength DCS flow-oximeter used two source fibers (core diameter of each fiber = 200 
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µm, emission area = 0.13 mm
2
) that were bundled tightly together (Figure 2.11c). To 
increase the SNR, signals from the 4 APDs were spatial averaged. The S-D separation 
was set to 2.5 cm for cerebral hemodynamic measurement. The probe pads used in DCS 
flowmeter (Figure 2.6a) and DCS flow-oximeter (Figure 2.11b) were very similar. DCS 
flow-oximeter shared the same source and detector fibers for both blood flow and 
oxygenation measurements, thus, it probed tissue hemodynamic parameters at an 
identical region of tissues. 
 Table 2.1 shows the comparison among hybrid NIRS/DCS devices and DCS 
flow-oximeter. Compared to the hybrid NIRS/DCS devices, DCS flow-oximeter 
measures the relative oxygenation changes, but is more portable, less expensive, and 
easier to operate. The upgraded hybrid NIRS/DCS employs a dual-mode autocorrelator 
which significantly improves the sampling rate, although it is bigger than the first 
generation hybrid instrument due to the increased number of DCS detectors. 
Table 2.1 Comparison among hybrid NIRS/DCS devices and DCS flow-oximeter 
 
Hybrid NIRS/DCS device 
DCS flow-oximeter 
Generation I Upgraded 
Measurement 
Outcomes 
rCBF, [Hb], 
[HbO2], THC, StO2 
rCBF, [Hb], 
[HbO2], THC, StO2 
rCBF, Δ[Hb], 
Δ[HbO2], ΔTHC 
Autocorrelator Continuous mode 
Continuous and 
Burst modes 
Continuous mode 
Dimensions 18”x24”x42” 32”x24”x42” 13”x21”x18” 
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Appendix I: Analytical Solutions of Photon Diffusion Equation in Different 
Geometries  
Analytical solutions in homogenous medium under infinite geometry. 
Analytical solutions of    ,    , and   in Equations 2.14 and 2.15 exist for 
homogeneous medium under infinite geometries (Figure 2.4a)  
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where x is defined as      . Then Equations 2.33 to 2.35 can be rewritten as Equations 
2.16 to 2.18 shown in Chapter 2.2.3. 
Analytical solutions in homogenous medium under semi-infinite geometry. 
Under semi-infinite geometry (Figure 2.4b), the detected photon fluence rate can be 
calculated as the superposition of the infinite solution from the positive isotropic source 
(at z = z0) and the negative imaging source (at z = -z0 - 2zb) [116, 117]. The solution for 
DC component (   ) is 
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Here,    √      ,     √             (Figure 2.4b). Similarly, the 
solutions for    and   are: 
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 To demonstrate the linear dependence of the logarithm of    and    and   on 
 , we rewrite Equations 2.36 to 2.38 as: 
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where FDC, FAC, Fφ, GDC, and GAC are defined by expanding the terms in Equations 2.36 
to 2.38. The slopes of the straight lines (    ,     , and    ) can be fitted from the 
measured values in the LHS of Equations 2.39 to 2.41 at different  , respectively. Note 
that the slopes under semi-infinite geometry are defined by the same equations under 
infinite geometry (Equations 2.19 to 2.21). Thus using Equations 2.22 and 2.23, one can 
extract    and   
  from the fitted slopes under semi-infinite geometry.  
Overall, we extract    and   
  from Equations 2.40, 2.41, 2.22, and 2.23, 
iteratively. More specifically, we ignore the terms that have    and   
  (i.e., assuming 
  = 0 and   
   ) on the LFH of the Equations 2.39 to 2.41 and obtain the slopes of 
       ,        , and       , and from which we determine       and   
     using 
Equations 2.22 and 2.23, where 0 indicates the initial guess. We then use these values to 
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obtain        ,        , and       ,      , and   
    , where “1” represents the first 
iteration. We continue applying this procedure recursively until       and   
     
reproduce themselves within a difference of less than 0.1%. Here i represents the number 
of iterations. The convergence is usually reached after a few iterations. 
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Appendix II: Derivation of Correlation Diffusion Equation  
 
Figure 2.12 Single dynamic light scattering experiment. 
 
Single scattering events. In a single scattering DLS experiment, photons are 
usually scattered once (or not at all) before they leave the sample (Figure 2.12). A point-
like photon detector is placed at an angle θ = kout - kin relative to the propagation direction 
of input beam. If the scatterers are moving, then the total electric field (E(t)) will vary in 
time and light intensity (I = 〈          〉 ) fluctuations are observed. Thus the 
fluctuations of the electric field/light intensity are linked to dynamic properties of the 
medium, i.e., the motion of the particles/scatterers. The normalized temporal 
autocorrelation function of the scattered electric field (     ) for CW light source is: 
       
〈            〉
〈          〉
   
 
 
  〈      〉
 (2.42)  
Here,   is the autocorrelation delay time,       
          is the square of the 
scattering wavevector,    
   
 
 is the wavevector magnitude of the incident light field, n 
is the index of refraction of the medium,   is the wavelength of the light field, and 
〈      〉 is the mean square displacement of the scatterers in the medium, which directly 
characterizes the particle movement.  
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Multiple scattering events. In case of photon transportation in biological tissue, 
multiple scattering effects are usually involved. Each scattering event from a moving 
scatterer contributes to the accumulation of the phase shift mentioned in Chapter 2.2.3 
and also the decay of the electric field correlation function. If we assume the electric 
fields from individual photon path (Figure 2.1) are uncorrelated, the total temporal field 
autocorrelation function can be expressed as the weighted sum of the field autocorrelation 
function from each photon path. Furthermore, if we assume a homogeneous medium, and 
further assume that each scattering event is independent and that scatterers’ 
displacements are uncorrelated, the field autocorrelation function from a single path can 
be written as: 
               
 
 
 
  
  〈      〉
 (2.43)  
where       〈    〉  , and 〈    〉  is the average value of cosine over all the N 
scattering events along the path. When N is large, the average value approaches the 
ensemble average, 〈    〉 , which is usually denoted by the so-called anisotropy factor 
(g) of the medium. The reduced photon scattering length or random-walk step length is 
  
      
           〈    〉   , where    is the scattering coefficient of the 
medium [118]. Let S represents the total pathlength associated with a particular photon 
path. Then the number of scattering events associated with this same path is N = s/   
  
   〈    〉  , and Y = s/   
  equals the total number of photon random-walk steps 
associated with the photon path.  
The final detected electric field autocorrelation function includes the contributions 
of all photon paths. If we use P(Y) to represent the probability distribution for photon 
paths with a number of random walk steps, Y, then the total electric field autocorrelation 
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function can be computed by incoherently integrating the contributions from each photon 
path [96, 119], that is.: 
       ∫     
 
 
  
 
 
  
  〈      〉   (2.44)  
In a highly scattering medium, Equation 2.44 can be equivalently expressed as an 
integral over all possible pathlengths using the pathlength distribution [96, 120, 121], 
P(s), i.e., 
       ∫     
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   (2.45)  
Equation 2.45 is the primary result from diffusing-wave spectroscopy (DWS) for 
a homogeneous turbid scattering medium composed of moving particle-like scatterers. 
The DWS correlation function is typically measured at some point inside the sample or 
on its surface, and P(s) depends implicitly on both measurement location and source 
position.  The distribution of P(Y) can be readily obtained from Monte Carlo simulation 
[122]. Alternatively, derivation of P(s) can be obtained experimentally from the 
normalized photo fluence rate (  ) from a TD NIRS measurement [123-126]. For 
example, the solution to a pulsed CW light source with                        is: 
        
          
∫         
 
 
 
          
    
 (2.46)  
where r is the location inside or on the surface of the turbid medium, S0 is the power of 
the CW source.  
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 Correlation diffusion equation. Unnormalized electric filed temporal 
autocorrelation         =              is linked with the           using Equations 
2.45 and 2.46: 
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Following Ref [93], we can do a simple replacement of variables (s = vt), multiply 
    , where    
 
   
   
 〈      〉 to both sides of Equation 2.9 and integrate s from 0 to 
∞, 
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The first and second terms on the LHS of Equation 2.48 is simplified as 
           and           . The third term on LHS of Equations 2.48 can be calculated 
as         by integrating             
    over s. Thus the RHS yields: 
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We combine the results above and simplify Equations 2.48 as: 
                               
 
 
   
   
 〈      〉        (2.50)  
By rearranging the above equation and dividing both sides by D ≃ v/3  
 , we get 
the correlation diffusion equation in homogenous medium for CW light source:  
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CHAPTER 3 DIFFUSE OPTICAL EVALUATION OF CBF AND CA IN 
PATIENTS WITH OBSTRUCTIVE SLEEP APNEA (OSA)  
3.1 Background 
OSA is characterized by repetitive episodes of upper airway obstruction during 
sleep that disturbs sleep architecture and induces intermittent hypoxia, and it affects 15 
million adult Americans [9, 10]. OSA episodes are associated with surges in blood 
pressure, hypercapnia, and fluctuations in CBFV/CBF. The OSA episode and breath 
holding maneuver perturb the cerebral circulatory control because of the hypoxia [127-
130]. Specifically, systemic blood pressure and CBFV increase progressively during the 
apnea followed by an abrupt decrease in both during the post apnea hyperventilation 
period. These perturbations can adversely affect CA [13], leading to cerebral impairment 
or brain dysfunction.  
Several studies have quantified dynamic CA in patients with OSA via measuring 
CBFV by TCD and MAP by finger plethysmograph [13, 131]. Nasr et al have found that 
the correlation coefficients between the MAP and CBFV in middle MCA were 
significantly higher in patients with OSA (n = 11) than those in healthy controls (n = 9) 
[131]. The higher correlation between the MAP and CBFV found in patients with OSA, 
indicating a worse CA. Urbano et al quantified dynamic CA in TD  using orthostatic 
hypotension as an autoregulatory stimulus [13]. A sudden standing after 2-minute 
squatting was adopted to induce a decrease in MAP. Compared to control subjects (n = 
26), significantly lower recovery rate of cerebral vascular conductance (i.e., slope of 
CBFV/MAP) were found in patients with OSA (n = 22), indicating an impaired CA [13].  
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Structural (e.g., the gray and white matter loss [132]) and functional (e.g., 
attention deficit, memory loss, impaired executive functions [12]) damages found in 
patients with OSA are usually associated with abnormal microvasculature [74]. However, 
due to the lack of techniques for CBF measurements, no one has ever quantified dynamic 
CA in microvasculature in this patient population. DCS offers noninvasive and 
inexpensive measurement of CBF, thus allowing for the evaluation of microvascular CA 
in patients with OSA.  
Several physiological manipulations have been used as the autoregulatory stimuli 
in testing dynamic CA, including bilateral thigh pressure cuff deflation [23], squat-to-
standing [13], head-up tilt (HUT) [133], and voluntarily breath holding [134]. Cuff 
inflation/deflation, squat-to-standing and HUT protocols create a MAP drop due to the 
reduction of cardiac outputs. However, the position changes during squat-to-standing and 
HUT may result in motion artifacts in MAP and optical measurements. The MAP 
measurement by the finger plethysmograph is sensitive to the relative height difference 
between the subject’s heart and finger sensor. The voluntarily breath holding is a 
subjective test. Therefore, the bilateral thigh pressure cuff inflation/deflation protocol was 
selected in this study as an autoregulatory stimulus for dynamic CA test. 
 
3.2 Methods 
3.2.1 Subjects 
Eleven (11) healthy controls and 13 patients with OSA participated in this study 
(Table 3.1) with signed consent forms approved by the University of Kentucky 
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Institutional Review Board. The apnea-hypopnea index (AHI), defined as apnea and 
hypopnea events occurred per hour during sleep, was used to classify the severity of OSA 
(i.e., healthy: AHI < 5, mild: 5 < AHI < 15, moderate: 15< AHI < 30, severe: AHI > 30) 
[135]. 
Table 3.1 Subject characteristics 
 
Total 
Number 
Female Male 
Age 
(year) 
Body Mass 
Index (BMI) 
(kg/m
2
) 
Apnea-
Hypopnea Index 
(AHI) 
Healthy 
Controls 
11 7 4 
42 ± 16 
(23~68) 
24 ± 4 
(18~32) 
< 5 
OSA Patients 13 7 6 
53 ± 13 
(35~69) 
39 ± 11 
(22~58) 
53 ± 43 
(10~122) 
 
3.2.2 Experimental Protocol 
The subject laid supine on a table and his/her MAP was continuously monitored 
by a finger plethysmograph (Figure 3.1). The finger sensor for MAP measurements was 
placed on the subject’s middle finger of left hand with his/her left arm fully extended at 
the same level of the heart. A DCS flowmeter was used to continuously monitoring CBF. 
A fiber-optic probe containing a multimode source fiber (x 1) and a single mode detector 
fiber (x 1) was taped on the middle of forehead for CBF measurement. An elastic 
bandage was used to wrap around the forehead to secure the probe and reduce the 
influence of room light. The measured light intensity was limited by the use of single-
mode fiber for DCS detection, thus restricting the use of large S-D separation. The 
separation was set at 2.5 cm which allowed for the detection of cerebral hemodynamics 
in adult prefrontal cortex [25, 38, 61, 63, 64, 68, 108]. The sampling rate for CBF and 
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MAP was 0.64 Hz (1/1.56 s). After baseline measurements for 5 minutes, both thighs of 
the subject were occluded by two cuff occlusion machines (Aspen ATS1000, Zimmer 
Inc., IN, USA) at a pressure of 230 mm Hg for 5 minutes. The pressures on both thighs 
were then rapidly and concurrently released.  
 
Figure 3.1 Experimental setup for assessing CBF and dynamic CA in patients with 
OSA. 
 
3.2.3 Data Analysis.  
Dynamic changes in MAP and rCBF after cuff deflation were defined as ΔMAP 
(mm Hg) and ΔrCBF (%), which were calculated as ΔMAP = MAPmean - MAPmin and 
ΔrCBF = rCBFmean - rCBFmin. Here MAPmean and rCBFmean were the averaged data from 
the 20-second before cuff deflation, and MAPmin and rCBFmin were the minimum values 
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within 30 seconds after cuff deflation in MAP and rCBF, respectively (Figure 3.3). The 
negative ΔMAP or ΔrCBF indicated a decrease in MAP and rCBF. CA index (CAI) was 
calculated by ΔrCBF/ΔMAP (% / mm Hg), indicating the change of cerebral vascular 
conductance. Two-tailed Student t-test was used for statistical analysis. A p-value less 
than 0.05 indicated a significant difference. 
 
3.3 Results 
3.3.1 Individual Results 
 
Figure 3.2 Typical MAP (a) and rCBF (b) results in response to cuff deflation in one 
healthy subject. 
 
Figure 3.2 shows typical time course responses of MAP and rCBF before, during 
and after cuff deflation measured in one healthy subject. After cuff deflation, MAP and 
rCBF decreased immediately and then recovered in a short time. Figure 3.3 shows typical 
results after cuff deflation in a patient with OSA (a) and a healthy control (b). Smaller 
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ΔMAP and ΔrCBF were found in the patient with OSA (ΔMAP = -8.8 mm Hg and 
ΔrCBF = -15%) than those in the control subject (ΔMAP = -17 mm Hg and ΔrCBF = -
32%).  
 
Figure 3.3 Typical ΔMAP and ΔrCBF responses in a patient with OSA (a) and a 
control subject (b). 
The vertical lines indicate the beginning of cuff deflation. The horizontal dashed lines 
represent the mean values of rCBF/MAP before cuff deflation. The green triangles show 
the minimum values of rCBF/MAP within 30 seconds after cuff deflation. The red lines 
with arrows show relative changes of rCBF/MAP after cuff deflation.  
 
3.3.2 Average Results 
On average (Figure 3.4), significantly smaller (p = 0.014) ΔrCBF was found in 
the OSA group (-17 ± 9%) compared to the control group (-26 ± 8%). The OSA group 
also had a significantly lower (p = 0.005) ΔMAP (-8.6 ± 4.5 mmHg) compared to the 
control group (-15.0 ± 5.5 mmHg). However, there was no significant difference (p = 
 
54 
0.967) in CA index (CAI) between the OSA (0.023 ± 0.014 %/mm Hg) and control 
(0.019 ± 0.008 %/mm Hg) groups. 
 
Figure 3.4 Average results of ΔMAP (a), ΔrCBF (b), and CAI (c) in the control and 
OSA groups. 
 
3.4 Discussion and Conclusions 
Previous studies have shown that quantifying recovery rate of cerebral vascular 
conductance in MCA can be used for the evaluation of TD dynamic CA in large vessels 
[13]. However, the CBFV in large arteries does not always reflect the CBF in brain 
microvasculature [38]. In the present study, we have evaluated TD dynamic CA in frontal 
cortex, for the first time, using the rCBF and MAP measured by the novel DCS and a 
commercial finger plethysmography during bilateral thigh pressure cuff deflation.  
Compared to healthy subjects, the smaller changes in MAP after cuff deflation in 
patients with OSA might be due to the less vasodilation in the lower extremities. The 
impaired endothelial function in patients with OSA [136] may have impaired the 
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vasodilation ability which is related to nitric oxide mechanisms [137]. Moreover, high 
sympathetic nervous activity has been found in patients with OSA [138], which can cause 
high resting constriction tone of blood vessels. The less decrease in MAP after cuff 
deflation may lead to the small changes in rCBF in the patient group. More investigations 
are needed to confirm these hypotheses.  
Surprisingly, we couldn’t find significant difference in CAI between the control 
and OSA groups during cuff deflation. The relatively small changes in MAP (< 15 mm 
Hg) created by the cuff deflation were much less than the CA range (60 ~ 150 mm Hg) 
[139], which might be the major reason contributing to this surprise. In other words, both 
patients and healthy controls might be able to maintain a stable CBF when there were 
relatively small disturbances in MAP. However, the small number of subjects with large 
inter-subject hemodynamic variations may also play a role for this surprise. Furthermore, 
the relatively low sampling rate (0.64 Hz) of DCS measurements working under the 
continuous mode might bring errors in quantifying rapid changes in rCBF and MAP 
during cuff deflation.  
More subjects are needed to increase the statistical power of our study. A DCS 
flowmeter with higher sampling rate (e.g., working in the burst mode) is needed to detect 
rapid dynamic changes in CBF in response to the autoregulatory stimulus. Other 
physiological manipulations should be explored to create larger MAP changes with less 
inter-subject variations for testing potential CA impairments in patients with OSA. 
Nevertheless, DCS flowmeter shows potential for detecting CBF directly and evaluating 
dynamic CA in cerebral microvasculature.    
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CHAPTER 4 DIFFUSE OPTICAL EVALUATION OF SPONTAENOUS LOW 
FREQUENCY OSCILLATIONS (LFOS) IN CEREBRAL HEMODYNAMICS  
4.1 Background 
As mentioned early (Chapter 1.2), dynamic CA can be evaluated in time-domain 
(TD) and frequency-domain (FD). TD methods (see the example in Chapter 3) quantify 
dynamic CA from the rapid changes of MAP and CBF/CBFV in the short period (e.g., 
~30 seconds during bilateral thigh pressure cuff deflation, see Chapter 3) during 
autoregulatory stimulus, which greatly relies on the SNR of the detected signals in the 
short period with limited data points. By contrast, FD methods (e.g., quantification of the 
phase shifts in LFOs between the MAP and cerebral hemodynamics) extract dynamic CA 
from the relatively stable data of MAP and cerebral hemodynamics in a relatively long 
period (e.g., 10 minutes). It is expected that more data points with smaller variations 
should provide better SNRs. Furthermore, LFO phase shift depends mainly on the 
relation of oscillation frequencies of MAP and cerebral hemodynamics rather than on the 
detected signal intensities, which should provide more robust results. We thus started 
testing dynamic CA in FD.  
In 1876, Mayer first found the spontaneous LFOs around 0.1 Hz in blood pressure 
which were later named as “Mayer waves” [140]. The LFOs in blood pressure are 
believed to be originated from residual oscillations of baroreflex at ~0.1 Hz [141]. With 
the development of noninvasive techniques for cerebral hemodynamic measurements, 
people have also detected LFOs in CBFV of MCA by TCD [142], in cerebral blood 
oxygenation quantified by NIRS [143], and in BOLD signal measured by fMRI [144]. 
 
57 
The CBF control mechanism underlying blood pressure oscillations may be extracted 
from the relationship between LFOs of ABP and cerebral hemodynamics, therefore 
holding potential for evaluating dynamic CA in FD [7, 18] and neurocognitive function 
[29]. For example, the decrease/increase in phase lead/lag of LFOs between 
CBFV/oxygenation and ABP in patients with carotid artery stenosis had been found by 
Reinhard et al. [7]. Wang et al. also showed that cerebral functional connections extracted 
from LFO signals of BOLD MRI were different in patients with impaired neurocognitive 
function (i.e., Alzheimer disease) compared to healthy subjects [145]. 
 It is relatively easy to measure LFOs in resting state, but previous results showed 
weak oscillations at rest [142, 146, 147]. Physiological manipulations have been applied 
in subjects in order to increase the SNRs of LFOs, such as HUT [142, 146, 147] and 
paced breathing at 0.1 Hz [7, 26, 148]. HUT increases sympathetic nervous activity, thus 
elevating LFOs in cerebral hemodynamics and MAP [142]. During paced breathing, a 
superimposed strong 0.1 Hz oscillation enhances the LFOs of both MAP and cerebral 
hemodynamics. However, complex chemical and neural reactions disturbing CA may be 
created from the change of respiratory rate during paced breathing.  
The goal of this study was to find the most sensitive cerebral hemodynamic 
variables and the most robust protocols for evaluating dynamic CA. For this purpose, I 
upgraded a hybrid NIRS/DCS instrument to achieve a higher sampling rate and a better 
SNR (Chapter 2.4). With these improvements we successfully detected LFO signals in 
cerebral hemodynamics which cannot be extracted by the previous generation I hybrid 
device (Figure 2.7). Using this upgraded instrument, CBF, [HbO2], [Hb] and THC were 
continuously monitored at rest, during 70° HUT, and during paced breathing at 0.1 Hz in 
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15 healthy subjects. Power spectral analysis was used to extract LFOs from the measured 
variables [24], and transfer function analysis was used to calculate the corresponding 
phase shifts and coherences of LFOs between the MAP and each of the measured 
cerebral hemodynamic parameters [7, 142, 148]. Reliable LFOs between the paired 
signals were selected based on the levels of coherence. The success rates of capturing 
LFOs of hemodynamic variables under the three physiological conditions were finally 
compared to determine the best hemodynamic parameter among the measured variables 
and optimal physiological condition in detecting cerebral hemodynamic LFOs. 
 
4.2 Methods 
4.2.1 Subjects 
Fifteen young healthy adults participated in this study with signed consent forms 
approved by the University of Kentucky Institutional Review Board. The average age of 
subjects was 27 ± 5 years.  
 
4.2.2 Experimental Protocols 
Cerebral hemodynamic parameters and MAP were simultaneously measured by 
the upgraded hybrid NIRS/DCS instrument and a finger plethysmograph under three 
conditions: at rest, during HUT and during paced breathing at 0.1 Hz (Figure 4.2). The 
sampling rate of measurements for all physiological parameters was ~2 Hz. The subject 
lay supine on a tilting table (Hausmann Inc., USA) and then was immobilized by two 
Velcro straps placed over the chest and thighs. A padded cushion was used to place the 
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left forearm at the heart level. The plethysmograph sensor was put on the middle finger of 
left hand and monitored the beat-to-beat MAP (mm Hg) continuously. Two fiber-optic 
probes were taped on the left and right sides of the forehead respectively at a position 
about 2 cm from the midline and 1 cm above the eyebrows (Figure 4.1a). A self-adhesive 
elastic band was then stretched around the forehead to fix both probes tightly and 
minimize the influence of room light on optical measurements. All data were 
continuously recorded throughout the experimental protocols which included 10 min 
baseline at rest, 10 min HUT at 70°, 10 min break after HUT back to 0°, and 10 min 
paced breathing at 0.1 Hz (Figure 4.2). During HUT test, the left forearm was held by an 
adjustable medical sling to keep the pressure sensor at the heart level. Before the test, 
each subject was trained to breathe regularly at 0.1 Hz following audio cues made by 
Microsoft PowerPoint. During experiments, room light was turned off to reduce the 
influence of ambient light. 
 
Figure 4.1 Placement of two hybrid fiber-optic probes on the forehead (a), and 
experimental setup (b) for noninvasive measurements of LFOs in cerebral 
hemodynamics. 
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Figure 4.2 Experimental protocols. 
 
4.2.3 Data Analysis  
Although the Imagent could measure the absolute values of tissue blood 
oxygenation (i.e., [HbO2], [Hb], THC, StO2) [76, 81], the measured time courses of 
absolute values were found too noisy to extract reliable LFOs. This was mainly due to the 
unstable phase slopes over time. Thus, the phase data were ignored from our analysis. We 
used the measured amplitudes at the two wavelengths from a single S-D pair (S-D 
separation = 3 cm) to calculate the relative changes of cerebral blood oxygenation (i.e., 
Δ[HbO2] and Δ[Hb]) based on MBLL [50, 64] (Chapter 2.2.1). The molar extinction 
coefficients were found from the literature [87]. DPF values were calculated from 
measured absolute baseline values of µa and µs’ [81, 149], and were assumed constant 
over time. The ΔTHC was calculated by sum of Δ[HbO2] and Δ[Hb].  
According to the methods described in previous studies [7, 142, 148], power 
spectral densities (PSDs) of MAP and cerebral hemodynamic parameters (i.e., rCBF, 
Δ[HbO2], Δ[Hb], and ΔTHC) under the three physiological conditions (i.e., at rest, during 
HUT, and during paced breathing at 0.1 Hz) were used to determine the LFO intensities 
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in those physiological variables. The PSD was calculated using Welch’s method (Figure 
4.3) [24]. Briefly, the linear trend of ~10 min time-course dataset (~1200 data points at a 
sampling rate fs = ~2 Hz) for each variable under a specific physiological condition were 
removed firstly. Note that we excluded noisy data during the short periods of 
physiological state transition (i.e., table tilting up/down). The detrended data were then 
divided into 8 segments [7]. The two adjacent segments had 50% overlap [24]. Therefore 
each segment had a length of ~267 (1200*2/9) data points. A Hanning window was 
applied to each segment to decrease the effect of spectral leakage. The FD spectrum of 
each segment was calculated by fast Fourier transform: FFT(xseg). Here xseg indicated 
time-course data in one segment. One smooth spectrum Fx(f) was yielded by averaging 
the 8 spectra, where f was the frequency. The frequency resolution of the averaged 
spectrum was ~0.0075 Hz (fs/267). LFO intensity was calculated as PSDxx(f) = Fx*(f) 
Fx(f)/fs. Here f was in the low frequency range of 0.05 to 0.15 Hz and Fx*(f) was the 
complex conjugate of Fx(f). 
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Figure 4.3 Data analysis procedures to identify successful LFO measurements and 
extract phase shifts and leading times in cerebral hemodynamic parameters. 
 
CA has been hypothesized as a linear system with input of MAP and output of 
cerebral hemodynamics [7, 142, 148]. The property of this linear system (e.g., phase 
shifts between the inputs and outputs) quantified by transfer function analysis indicates 
the characteristics of CA. To perform transfer function analysis, cross spectral densities 
(CSDs) between MAP and each of the cerebral hemodynamic parameters were needed. 
Similar to the calculation of PSD, CSD were quantified by CSDxy(f) = Fx*(f) Fy(f)/fs 
(Figure 4.3). Here x and y indicated MAP and one of the cerebral hemodynamic 
parameters, respectively. The transfer function was then determined: H(f) = 
CSDxy(f)/PSDxx(f). Here PSDxx(f) represented the PSD of MAP. Using the equations: Φ(f) 
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= arctan[HI(f)/HR(f)] and Coh(f) = |CSDxy(f)|
2
/[PSDxx(f) PSDyy(f)], one could assess the 
phase shift and coherence between the paired signals. Here HI(f) and HR(f) were the 
imaginary and real parts of H(f), respectively.  
A high level of coherence represents a reliable and constant phase relationship 
between paired parameters. The success of LFO measurements and the relative phase 
shift thus can be determined by Coh(f). Based on previous studies [8, 150], if the largest 
Coh(f0) found in the low frequency range (0.05 < f0 < 0.15 Hz) was higher than 0.4 the 
LFO measurement was judged to be successful. The reliable LFO frequency and phase 
shift respectively were then determined by f0 and Φ(f0). The positive/negative Φ(f0) 
represented that the corresponding LFO of a hemodynamic parameter preceded/followed 
the LFO of MAP in time. LFO leading time (Tleading) could be converted from Φ(f0) by 
the equation: Tleading = Φ(f0)/360°/f0. The best parameter(s)/protocols(s) for future LFO 
study were determined by comparing the success rates of capturing reliable LFOs and 
phase shifts for all hemodynamic parameters under the three conditions in two 
hemispheres. Figure 4.3 shows a flowchart for better understanding the data analysis 
procedures described above. 
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4.3 Results 
4.3.1 Individual Results 
 
Figure 4.4 Typical time course responses of MAP and cerebral hemodynamics in a 
reprehensive subject. 
(a) MAP measured by the finger plethysmograph, (b) rCBF, and (c) to (e): cerebral 
oxygenation changes measured in the left and right hemispheres. The vertical lines 
indicate the beginning and end of different physiological conditions. 
 
Typical time-course data of MAP and cerebral hemodynamics throughout the 
entire protocol measured from one subject’s left and right hemispheres are shown in 
Figure 4.4. Over the entire experiment, similar average levels of MAP (~80 mm Hg) 
were observed at all physiological conditions (Figure 4.4a). Due to cerebral 
heterogeneous responses, slight differences existed in cerebral hemodynamics between 
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the left and right hemispheres (especially during HUT). However, bilateral response 
trends were same. Inverse responses were found in Δ[HbO2] and Δ[Hb], and Δ[HbO2] 
had larger changes. As the sum of Δ[HbO2] and Δ[Hb], ΔTHC followed the larger change 
of Δ[HbO2]. Relatively stable cerebral hemodynamic variables were found at rest, since 
there were no physiological changes. During HUT, rCBF decreased slightly due to the 
increase of cerebral vasculature resistance as well as the decrease of cardiac output 
induced by orthostatic stress [151]. Previous studies have also found reduced CBFV 
during HUT [152]. The decreased rCBF caused the reduction of oxygen delivery. 
Consequently, Δ[HbO2] decreased while Δ[Hb] increased. During the protocol of paced 
breathing at 0.1 Hz, MAP and cerebral hemodynamics showed slight fluctuations. In total, 
similar trends to this subject were observed in eight of the 15 subjects. However, the 
other seven subjects exhibited slight decreases in rCBF and Δ[HbO2] during paced 
breathing (data not shown). This was due to that the relatively slow and deep breathing at 
0.1 Hz might induce hypocapnia [150] and lead to a vasoconstriction. As a result, rCBF 
and Δ[HbO2] decreased in those subjects. 
Figure 4.5 shows typical PSDs of all measured physiological variations at the 
three physiological conditions. All PSDs were quantified from the time-course data of the 
same subject shown in Figure 4.4. Since similar results were found in both hemispheres, 
only data acquired from the left hemisphere are presented. At rest, small PSD peaks 
exhibited in MAP (Figure 4.5a1) and rCBF (Figure 4.5b1) in the low frequency range. 
During HUT, obvious peaks around 0.08 Hz were found in PSDs of all physiological 
variables (Figures 4.5a2, 4.5b2, 4.5c2, 4.5d2, and 4.5e2). Meanwhile, the PSD signals in 
the low frequency range were significantly enhanced. Similar to the results during HUT, 
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paced breathing at 0.1 Hz created PSD peaks around 0.1 Hz in all parameters (Figures 
4.5a3, 4.5b3, 4.5c3, 4.5d3, and 4.5e3). The intensities of LFOs were represented by the 
magnitudes of PSD(f) in the low frequency range (0.05 to 0.15 Hz). The SNR of LFOs in 
MAP and cerebral hemodynamic variables were improved in the protocols of HUT and 
paced breathing. Among these physiological variables, least SNR in detecting LFOs was 
found in Δ[Hb] (Figures 4.5d1, 4.5d2, 4.5d3).  
 
Figure 4.5 PSDs of MAP and cerebral hemodynamics under three physiological 
conditions in subject’s left hemisphere.  
(a1), (b1), (c1), (d1) and (e1): PSDs at rest; (a2), (b2), (c2), (d2) and (e2): PSDs during 
HUT; (a3), (b3), (c3), (d3) and (e3): PSDs during paced breathing. 
 
The relationship (phase shift and coherence) between the LFOs of each paired 
signals was shown in Figure 4.6. The data in Figure 4.6 were obtained from the same 
subject’s left hemisphere (Figures 4.4 and 4.5), and similar results were found in 
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subject’s right hemisphere (data not shown). At rest, all paired variables had low levels of 
coherence. The Coh(f) higher than 0.4 were only found in a few points (Figures 4.6a1, 
4.6b1, 4.6c1, 4.6d1). During HUT and paced breathing at 0.1 Hz, coherences higher than 
0.4 were mostly observed in the low frequency range of 0.05 to 0.1 Hz (Figures 4.6a2, 
4.6b2, 4.6d2) or 0.09 to 0.11 Hz (Figures 4.6a3, 4.6b3, 4.6c3, 4.6d3), except the pair of 
MAP and Δ[Hb] (Figure 4.6c2).  
 
Figure 4.6 Phase (Φ(f)) and coherence (Coh(f)) spectra of paired signals between the 
MAP and each of the cerebral hemodynamic parameters under three physiological 
conditions in subject’s left hemisphere. 
(a1), (b1), (c1) and (d1): spectra at rest; (a2), (b2), (c2) and (d2): spectra during HUT; 
(a3), (b3), (c3) and (d3): spectra during paced breathing. The solid lines represent the Φ(f) 
and the dashed lines represent the Coh(f). The horizontal dashed lines indicate the 
coherence threshold Coh = 0.4. The circles indicate the largest coherences within the low 
frequency range. The triangles indicate the most reliable phase shifts within the low 
frequency range. 
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4.3.2 Average Results 
 
Figure 4.7 Average PSDs of MAP and cerebral hemodynamic parameters over 
subjects (n = 15) under three physiological conditions in subject's left hemispheres. 
The solid curves indicate the mean value of PSDs while the dashed curves surrounding 
the dashed curve represent the range of data variations (standard errors). 
 
Fifteen healthy subjects were tested in this study. The average PSDs of MAP and 
cerebral hemodynamic parameters in the left hemispheres over 15 subjects under the 
three physiological conditions are presented in Figure 4.7. Data are shown as mean ± 
standard error. Results in the right hemispheres were similar (data not shown). Similar 
trends were found in the average and individual (Figure 4.5) PSDs. Δ[Hb] had smaller 
average LFO amplitudes under all physiological conditions (≤ 0.23 µM
2
/Hz) than 
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Δ[HbO2] (≥ 0.69 µM
2
/Hz) and ΔTHC (≥ 0.32 µM
2
/Hz). Compared to resting state, both 
HUT and paced breathing generated larger increases in LFO amplitudes. 
 
Table 4.1 Average LFO frequencies, leading times, phase shifts, and success rates of 
cerebral hemodynamic LFO measurements 
Number of Subjects (n = 15) 
Significant level of Coh (Coh > 0.4) 
Average LFO frequencies (Hz) 
Average leading times (second) 
Average phase shifts (degree) 
 (Number of successful measurements; Success rates) 
rCBF Δ[HbO2] Δ[Hb] ΔTHC 
Rest 
Left side 
0.078 ± 0.011 
1.77 ± 1.72 
49.3 ± 46.2 
 (13; 87%) 
0.079 ± 0.012 
1.54 ± 1.65 
48.6 ± 48.2 
 (10; 67%) 
0.080 ± 0.010 
0.08 ± 3.84 
4.7 ± 122.4 
 (7; 47%) 
0.078 ± 0.012 
0.76 ± 1.48 
23.6 ± 44.8 
 (11; 73%) 
Right side 
0.086 ± 0.014 
0.95 ± 1.61 
29.7 ± 49.9 
 (12; 80%) 
0.084 ± 0.010 
1.27 ± 1.17 
41.1 ± 32.8 
 (11; 73%) 
0.080 ± 0.008 
-0.93.± 3.11 
-31.1 ± 92.6 
 (9; 60%) 
0.083 ± 0.010 
0.26 ± 1.22 
7.0 ± 35.9 
 (11; 73%) 
HUT 
Left side 
0.076 ± 0.010 
1.65 ± 0.65 
45.7 ± 19.1 
 (15; 100%) 
0.076 ± 0.010 
1.16 ± 0.59 
29.5 ±11.8 
 (15; 100%) 
0.074 ± 0.009 
-1.18 ± 4.09 
-38.1± 117.1 
 (11; 73%) 
0.076 ± 0.009 
-0.37 ± 0.53 
-11.3 ±16.6 
 (15; 100%) 
Right side 
0.076 ± 0.010 
1.66 ± 0.63 
45.3 ± 16.7 
 (15; 100%) 
0.076 ± 0.010 
0.96 ± 0.59 
24.4 ± 12.7 
 (15; 100%) 
0.076 ± 0.011 
-1.48 ± 4.06 
-45.6 ± 99.6 
 (13; 87%) 
0.076 ± 0.009 
-0.54 ± 0.69 
-16.9 ± 22.5 
 (15; 100%) 
Paced breathing 
at 0.1 Hz 
Left side 
0.098 ± 0.003 
2.14 ± 2.40 
68.0 ± 88.9 
 (14; 93%) 
0.097 ± 0.002 
1.42 ± 0.82 
68.9 ± 45.4 
 (14; 93%) 
0.098 ± 0.007 
-0.03 ± 2.91 
-16.2 ± 111.3 
 (13; 87%) 
0.097 ± 0.002 
0.57 ± 1.24 
20.1 ± 41.4 
 (15; 100%) 
Right side 
0.097 ± 0.002 
2.60 ± 2.11 
77.7 ± 80.4 
 (14; 93%) 
0.098 ± 0.003 
1.66 ± 0.93 
60.3 ± 32.7 
 (15; 100%) 
0.097 ± 0.002 
-0.97 ± 3.04 
-22.9 ± 99.7 
 (13; 87%) 
0.097 ± 0.002 
0.47 ± 1.24 
9.3 ± 41.6 
 (15; 100%) 
 
Reliable LFOs and phase shifts were selected by the coherence level larger than 
0.4 (Chapter 4.2.3). Table 4.1 and Figure 4.8 show the summary of LFO frequencies, 
leading times, phase shifts, and success rates for detecting reliable LFOs. Data are shown 
as mean ± standard deviation unless otherwise noted. Since the LFO leading times were 
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calculated from phase shifts, leading times and phase shifts revealed equivalent 
information about the relationship between the MAP and cerebral hemodynamic 
parameters. For simplicity, we only discuss phase shifts. Δ[Hb] results (Table 4.1 and 
Figure 4.8) are excluded in the following reports due to its large signal variations (92.6° ≤ 
std(Φ) ≤ 122.4°) and low success rates (47 to 87%).  
 
Figure 4.8 Average phase shifts of cerebral hemodynamics relative to MAP over 15 
subjects under three physiological conditions in left and right hemispheres. 
(a) phase shifts at rest; (b) phase shifts during HUT; (c) phase shifts during paced 
breathing. For cerebral hemodynamic data, the solid and dashed curves demonstrate the 
signals obtained form left and right hemispheres, respectively. The vertical lines indicate 
the peaks of MAP oscillations. The empty circles indicate the peaks of cerebral 
hemodynamic oscillations. The error bars represent the standard deviations of the phase 
shifts. 
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At rest, relatively low success rates (67 to 87%) were observed in detecting LFOs. 
Moreover, LFO frequencies were obtained in a relatively wide range (0.078 to 0.086 Hz). 
The phase shifts exhibited relative large standard deviations (32.8° ≤ std(Φ) ≤ 49.9°). 
Also, relatively large differences between the phase shifts in left and right hemispheres 
were obtained in cerebral hemodynamic parameters (7.5° ≤ |Φleft - Φright| ≤ 19.6°).  
During HUT, success rates in capturing LFOs were 100% for all hemodynamic 
parameters (except Δ[Hb]) from both hemispheres. LFO frequencies appeared at ~0.076 
Hz. Compared to the results at rest, the standard deviations of phase shifts were much 
smaller (11.8° ≤ std(Φ) ≤ 22.5°) during HUT (Table 1 and Figure 4.8). There were minor 
differences in phase shifts between left and right hemispheres (0.4° ≤ |Φleft - Φright| ≤ 5.6°). 
During paced breathing at 0.1 Hz, rCBF, Δ[HbO2] and ΔTHC showed high 
success rates (93 to 100%). LFO frequencies exhibited at ~0.1 Hz as expected. However, 
phase shifts had much larger standard deviations (32.7° ≤ std(Φ) ≤ 45.4° for Δ[HbO2] and 
ΔTHC, and 80.4° ≤ std(Φ) ≤ 88.9° for rCBF) compared to those during HUT (Table 1). 
Also, phase shift differences between left and right hemispheres (8.6° ≤ |Φleft - Φright| ≤ 
10.8°) were larger than those exhibited during HUT. 
 
4.4 Discussion 
4.4.1 NIRS/DCS Technologies Facilitate Detection of LFOs in Cerebral Hemodynamics 
Although NIRS has been previously employed to investigate LFOs in cerebral 
microvasculature [7, 148], it cannot measure tissue CBF directly. Moreover, cerebral 
tissue hemodynamics (i.e., CBF and cerebral oxygenation) are usually interactive and 
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coupled. It is thus crucial to directly and simultaneously quantify multiple cerebral 
hemodynamic parameters in microvasculature. Nevertheless, only a few studies have 
aimed to concurrently detect LFOs in CBFV and cerebral oxygenation [7, 153]. In the 
present study, we demonstrated, for the first time, that DCS can detect LFOs of CBF and 
that the upgraded hybrid NIRS/DCS device can simultaneously capture multiple LFOs of 
cerebral hemodynamic variables (i.e. rCBF, Δ[HbO2], Δ[Hb] and ΔTHC). Multiple 
hemodynamic parameters from both cerebral hemispheres were simultaneously acquired 
using two hybrid fiber-optic probes, and then used to calculate cerebral LFOs.  
 
4.4.2 Comparison of LFOs among Different Hemodynamic Parameters under Different 
Physiological Conditions 
Among these hemodynamic parameters, LFOs of rCBF, Δ[HbO2] and ΔTHC had 
relatively stable phase shifts (std(Φ) ≤ 88.9°) and were detected at reasonable success 
rates (≥ 67%) under the three physiological conditions. Compared to other variables, 
LFOs of Δ[Hb] were much weaker, which agreed with previous findings [7, 148]. As a 
consequence, the phase shifts of Δ[Hb] had large variations. The weak LFOs of Δ[Hb] 
were likely caused by the low amplitude of Δ[Hb] in cerebral blood. Cerebral blood has a 
high oxygen saturation varying from almost 100% in arterial blood to ~60% in venous 
blood, indicating the small percentage of [Hb] in cerebral blood [154]. It is also possible 
that the cerebral venula (containing more [Hb]) is less responsible to blood pressure 
variations than the arteriole (containing more [HbO2]) [155]. As a result, Δ[Hb] exhibited 
the least magnitude and SNR of LFOs, and was therefore excluded from the following 
discussions. 
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LFOs at rest were weak, resulting in low SNRs [150]. As a result, success rates 
were low and LFO frequencies, phase shifts, and phase differences between the two 
hemispheres had large variations (SDs) at rest. HUT and paced breathing significantly 
enhanced LFOs through different mechanisms. During paced breathing, LFOs at 0.1 Hz 
were elevated by respiration-induced MAP oscillation [150]. However, there were large 
inter-subject variations in phase shifts of cerebral hemodynamics, which might be 
attributed to the heterogeneous responses to paced breathing among subjects. The 
hypocapnia might be induced by relatively deep and slow breathing pattern used in the 
present study, resulting in increased variations in cerebral hemodynamics [150]. LFOs 
during HUT were enhanced probably through the increased sympathetic nervous activity 
[142, 151]. Previous study has demonstrated that a single burst in sympathetic nervous 
system can initiate a cycle of increasing and decreasing arterial pressure at ~0.1 Hz via 
the baroreflex feedback loop [156]. The sympathetic nervous activity bursts in series each 
~10 s during HUT [157], which can significantly enhance LFOs of MAP through 
baroreflex resonance. Moreover, compared to the paced breathing protocol, the HUT 
protocol is easier to control and more objective. Overall, signals obtained during HUT 
were most stable (smallest standard deviations) and robust (highest success rates) among 
the three physiological conditions. 
 
4.4.3 Comparison of LFO Measurements with Other Studies 
Transfer function analysis has been used by several research groups to study 
LFOs in cerebral hemodynamics at rest [142, 146, 147], during HUT [142, 146, 147] and 
during paced breathing at 0.1 Hz [7, 26, 148]. However, no one has ever quantified 
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cerebral LFOs under all three physiological conditions in a single study. Therefore, our 
results were compared respectively to those with comparable data in corresponding 
physiological condition. 
At rest, success rates and phase shifts of LFOs in CBF measured by DCS (80% ≤ 
success rate ≤ 87%, 29.7° ≤ Φ ≤ 49.3°, n = 15) are in reasonable agreement with those of 
CBFV measured by TCD (92% ≤ success rate ≤ 100%, 44.9° ≤ Φ ≤ 56.3°, 20 ≤ n ≤ 50) 
[142, 146, 147]. 
During HUT, our results of LFOs in CBF (success rate = 100%, 45.3° ≤ Φ ≤ 45.7°, 
n = 15) are similar to those in CBFV (success rate = 100%, 40.6° ≤ Φ ≤ 50.2°, 20 ≤ n ≤ 
47) [142, 146, 147].  
It is not surprising that the LFO frequencies obtained during paced breathing at 
0.1 Hz in the present study are highly consistent with other studies [7, 26, 148]. During 
paced breathing, success rates for extracting reliable LFOs of cerebral hemodynamics (≥ 
93% for rCBF and Δ[HbO2], 100% for ΔTHC, n = 15) in the present study are close to 
those (100% for CBFV and Δ[HbO2], 97% for ΔTHC, n = 38) documented by Reinhard 
et al [7]. The phase shifts in CBF (68.0° ≤ Φ ≤  77.7°, n = 15) are also similar to those in 
CBFV (64.8° ≤ Φ ≤ 70.5°, 38 ≤ n ≤ 50) recorded by Reinhard et al and Diehl et al [7, 26]. 
However, inter-subject variations of phase shifts in CBF (80.4° ≤ std(Φ) ≤ 88.9°, n = 15) 
extracted in our study are much larger than those in CBFV (26.1° ≤ std(Φ) ≤ 29.8°, 38 ≤ 
n ≤ 50) [7, 26]. These large fluctuations might be attributed to the fact that the CBF in 
microvasculature is more sensitive to the hypocapnia induced by the paced respiration 
than the CBFV in large cerebral vessels [158]. In addition, the phase shifts of Δ[HbO2] 
(68.9 ± 45.4° and 60.3 ± 32.7° for the left and right hemisphere, respectively, n = 15) are 
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quite different from the results measured by Reinhard et al. (Φ = -23.5 ± 23.9°, n = 38) 
and Obrig et al. (Φ = ~0°, n = 3) [7, 148]. Phase shifts of LFOs in ΔTHC in our 
measurements (20.1 ± 41.4° and 9.3 ± 41.6° for the left and right hemisphere, 
respectively, n = 15) are also distinct from those (Φ = -22.6 ± 30.5°, n = 38) reported by 
Reinhard et al [7]. The causes for these differences are unclear. Several factors are likely 
to be involved, such as number of subjects and age differences among studies, tissue 
heterogeneity responses (e.g., different penetration depths using different S-D separations 
of 3 to 5 centimeters for oxygenation measurements), instrumentation differences (e.g., 
frequency-domain versus continuous-wave), vascular reactivity differences in response to 
CO2 oscillations during paced breathing, and subject training differences for controlled 
breathing. 
 
4.4.4 Study Limitations 
NIR measurements with S-D separations of 2.5 and 3 cm have similar sensitive 
areas and penetration depths. However, it should be noticed that optical fibers for DCS 
and NIRS in our hybrid fiber-optic probe (Figure 4.1a) were arranged in a special pattern 
to minimize the interference between DCS and NIRS measurements [77]. As a result, the 
centers of our DCS and NIRS fiber pairs were not aligned precisely in the plane of 
forehead, which may result in slight difference in detection regions for DCS and NIRS 
measurements. Tissue heterogeneous responses from different regions may lead to certain 
discrepancy between the DCS and NIRS measurements. 
 The physiological manipulations used (i.e., HUT and enforced breathing) in this 
study to enhance LFOs may not be easily performed in some patient populations. For 
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example, it may be difficult for patients with vascular diseases to keep their breathing at a 
low frequency of 0.1 Hz for 10 minutes. Furthermore, the HUT may induce vasovagal 
syncope in both health and disease populations [159]. 
Cerebral hemodynamics is also influenced by the changes in arterial carbon 
dioxide (CO2) content via changes in respiration (e.g., enforced breathing). Therefore, 
future study should also include the assessments of CO2 and respiratory rate [181].  
For comparison purposes, successful LFO measurements were characterized by 
coherence level larger than 0.4, which is an empirical value. In fact, the significant level 
of coherence should be determined statistically. More specifically, LFO measurements 
are considered successful if the coherence coefficient is significantly different from 0 
[150]. Using this objective criterion for judging the coherence level would increase the 
success rates of our LFO measurements. 
 
4.5 Conclusions 
A novel hybrid NIRS/DCS device was successfully upgraded and used for 
concurrent measurements of LFOs of rCBF and cerebral oxygenation (i.e., Δ[HbO2], 
Δ[Hb] and ΔTHC). Cerebral hemodynamic LFOs in the left and right hemispheres were 
measured and compared under three different physiological conditions (i.e., at rest, 
during HUT, and during paced breathing). rCBF, Δ[HbO2], and ΔTHC were found to be 
reliable hemodynamic parameters in detecting LFOs. Among the three physiological 
conditions, HUT was determined as the most robust and stable protocol for quantifying 
phase shifts of LFOs in hemodynamic parameters. Success rates in detecting cerebral 
LFOs were close to those in other relevant studies. Future study will investigate cerebral 
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LFOs in patients with cerebral disease/damage (e.g., stroke, carotid stenosis, and 
neurocognitive impairment) and evaluate their dynamic CA via the determination of LFO 
phase shifts. It is expected that direct and concurrent measurements of LFOs in CBF and 
cerebral oxygenation will bring new and informative perspectives about mechanisms of 
CA and pathologies of diseases/damages in the brain.  
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CHAPTER 5 DIFFUSE OPTICAL MONITORING OF CEREBRAL 
HEMODYNAMICS FOR THE PREDICTION OF VASOVAGAL SYNCOPE  
5.1 Background 
During the HUT tests as described in Chapter 4, several healthy subjects 
experienced vasovagal presyncope symptoms (i.e., a sudden drop in blood pressure, 
dizziness, blurred vision, sweating, and heart palpitation). Dramatic decreases in CBF 
were also observed in these subjects. It is known that when cerebral vasculature loses its 
ability to maintain the CBF above a critical level (i.e., failure of CA), vasovagal syncope 
(VVS) may occur [14]. Although our previous studies have evaluated dynamic CAs in 
TD (Chapter 3) and FD (Chapter 4), cerebral hemodynamics at the condition of losing 
CA has not been monitored. Therefore, more healthy subjects were recruited in this study 
to continuously monitor cerebral hemodynamics and MAP during VVS using the novel 
dual-wavelength DCS flow-oximeter (Chapter 2.5) and a finger plethysmography.  
VVS, the most commonly occurring syncope, has been widely studied using HUT 
test [15, 16]. Central hypovolemia [160, 161] and increased sympathetic outflow [161-
163] induced by HUT may eventually trigger a vasovagal reaction which is a 
malfunctioning of autonomic nervous system. The vasovagal reaction results in decreases 
in blood pressure and heart rate which may lead to VVS even in healthy volunteers [17]. 
The pathophysiology of vasovagal reaction is not fully known. However, sudden drops in 
arterial blood pressure, CBFV in the MCA, and cerebral oxygenation have been 
previously observed during VVS [164, 165]. Simultaneous and continuous quantification 
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of these physiological parameters during VVS is rare, but critical for predicting VVS and 
determining which variable eventually triggers VVS.  
The sudden decrease of blood pressure is well known to be an indicator for 
developing VVS. Thus, ABP has been measured continuously in previous studies using a 
finger plethysmograph or an invasive catheter [165-167]. TCD has been frequently used 
to monitor CBFV in large cerebral vessel (e.g., MCA) in these studies [165-167]. Some 
studies have measured ABP and CBFV [166] or ABP and cerebral oxygenation [168] 
simultaneously to determine which variable triggers VVS. Rapid declines in cerebral 
hemodynamics during VVS were found occurring earlier than ABP drops [166, 168]. So 
far very few studies have assessed dynamic changes of ABP, CBFV, and cerebral 
oxygenation concurrently during VVS [152, 167]. However, these studies did not intend 
to quantitatively determine the eventual trigger of VVS.  
In this study, a finger plethysmograph and a novel custom-designed dual-
wavelength DCS flow-oximeter (Chapter 2.5) were used to simultaneously monitor MAP, 
dynamic changes of CBF and concentration changes of oxygenated- (Δ[HbO2]), 
deoxygenated- (Δ[Hb]) and total hemoglobin (ΔTHC) in healthy subjects during 30-
minute 70° HUT tests. The ability of maintaining stable MAP, CBF and cerebral 
oxygenation was challenged by the HUT. Instability of these parameters may result in 
VVS. Dynamic changes in multiple physiological variables (i.e., MAP, CBF, Δ[HbO2], 
Δ[Hb] and ΔTHC) were continuously monitored during the postural change (i.e., HUT). 
The ultimate goals are to evaluate each parameter’s sensitivity to predict VVS and 
investigate which variable eventually triggers VVS.     
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5.2 Methods 
5.2.1 Subjects 
Table 5.1 Subject characteristics 
Subject Sex 
Age 
(years) 
Values at Supine HUT 
Duration 
(min) 
Valid Measurements during HUT 
MAP 
(mm Hg) 
HR 
(BPM) 
MAP 
(%) 
CBF 
(%) 
Oxygenation 
(%) 
Presyncope Group (N = 6) 
S1 F 57 95 70 15.4 √ √ √ 
S2 F 60 105 62 2.7 N/A √ N/A 
S3 F 60 81 71 10.6 √ √ N/A 
S4 F 39 82 77 5.9 √ √ √ 
S5 M 40 72 58 2.5 √ √ √ 
S6 M 24 96 50 9.3 √ √ √ 
 
Control Group (N = 8) 
C1 M 47 83 67 30.0 √ √ √ 
C2 M 55 77 70 30.0 √ √ √ 
C3 M 59 79 65 30.0 √ √ √ 
C4 F 51 95 77 30.0 √ √ √ 
C5 F 48 85 80 30.0 √ √ √ 
C6 F 46 75 61 30.0 √ √ √ 
C7 F 33 87 66 30.0 √ √ √ 
C8 M 26 80 63 30.0 √ √ √ 
 
Fourteen healthy adults (6 males and 8 females) without known cerebral or 
cardiac diseases were recruited in this study (Table 5.1). All participants signed consent 
forms approved by the University of Kentucky Institutional Review Board. Six (2 males 
and 4 females) out of the fourteen subjects experienced presyncopal symptoms (i.e., 
sudden drop in blood pressure, sweating, dizziness, blurred vision, and heart palpitation) 
during 70° HUT. For comparisons, the remaining 8 subjects without presyncope were 
used as a control group. MAP data from one subject with presyncope (S2) was excluded 
due to its poor SNR. Two subjects with presyncope (S2 and S3) did not have oxygenation 
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data since one of the two lasers in DCS flow-oximeter was not working properly during 
the measurements.   
 
5.2.2 Experimental Protocol 
Relative changes of rCBF, Δ[HbO2], Δ[Hb], and ΔTHC during HUT were 
monitored by the custom-designed dual-wavelength DCS flow-oximeter. Here “r” 
denotes the relative change with the unit %, while “Δ” indicates the absolute change in 
unit of μM. Details about the DCS flow-oximeter can be found in Chapter 2.5. A fiber-
optic probe was taped in the middle of forehead at the position of 1 cm above the 
eyebrows for the optical measurements of cerebral hemodynamic parameters. The 
separation between source and detector fibers was 2.5 cm. To fix the probe on the frontal 
head, a self-adhesive elastic band was used to wrap the probe tightly around the forehead. 
The noninvasive finger plethysmograph (Portapres, FMS Inc., Netherlands) was used to 
continuously monitor the beat-to-beat MAP in unit of mm Hg and heart rate (HR) in unit 
of beats-per-minute (BPM). The plethysmograph finger sensor on the middle finger of 
left hand was maintained at the heart level. Data sampling rate for both optical and 
MAP/HR measurements is 1 Hz. 
A 30-minute 70° HUT protocol was adopted in the present study, which is similar 
to the 10-minute 70° HUT protocol described in Chapter 4. This protocol was selected 
because previous studies had found that it may induce VVS in healthy subjects [159, 169]. 
More specifically, the subject was asked to lay supine on a tilt table. To immobilize the 
body, two Velcro strips were placed over the chest and thighs respectively. Following the 
supine control for ~10 minutes, the subject was tilted up to 70° and instructed to remain 
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still for 30 minutes if possible. However, when presyncopal symptoms appeared during 
standing at 70°, the subject was tilted back to supine position immediately for recovery. 
The recovery period at supine position was ~5 minutes.  
 
5.2.3 Data Analysis 
 To reduce high frequency noise, a 10-point sliding average was applied on all raw 
data. The averaged data from the 30-second right before the onset of HUT were used to 
represent their baseline values at supine position, since the supine MAP and HR were 
fairly stable. In order to compare HUT induced changes among the measured parameters 
(i.e., MAP, rCBF, Δ[HbO2], Δ[Hb], ΔTHC) with different units, we normalized (divided) 
all variables respectively to the averaged values of the 30-second data segment 
immediately after the tilt table was positioned to 70°. rMAP, rCBF, r[HbO2], r[Hb], and 
rTHC indicated the relative values normalized (divided) by their baseline values, 
respectively. For quantifying r[HbO2], r[Hb] and rTHC, baseline values of these variables 
were assigned to be 23.6, 13.0 and 37.5 µmol/L, respectively, according to the literature 
[170]. All baselines were assigned to be 100% after the normalization. 
Similar to previous results in others’ studies [163, 164, 167], subjects with 
presyncope exhibited two stages of physiological responses during HUT (see Figure 5.1 
and Figure 5.2 in Chapter 5.3): a slow and gradual change in each measured variable at 
Stage I before a break-point and a rapid and dramatic change at Stage II after a break-
point. In presyncope subjects, the maximum changes in all measured variables occurred 
at Stage II. To compare the sensitivities of measured variables for predicting VVS, we 
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quantified the minimum values of rMAP, rCBF, r[HbO2], and rTHC, and maximum of 
r[Hb] in control and presyncope subjects during HUT. To determine which variable 
trigged the VVS, we evaluated the onset time of rapid/dramatic dynamic changes before 
presyncope following the method suggested by Dan et al [166]. Briefly, the measured 
time course data during HUT for each variable were linearly fitted by two straight lines 
which represent the slow and rapid changes, respectively [166]. The two straight lines 
(Figure 5.1(b) and Figure 5.2(a)) were connected at a break-point. We moved the break-
point from the beginning to the end of HUT along each dataset, and calculated the 
corresponding mean squared errors (MSEs) of the linear best fittings. The final break-
point separating the two stages was selected at the time point where the smallest MSE 
was observed. Time differences of break-points between the rMAP and each of the other 
hemodynamic parameters (i.e., rCBF, r[HbO2], r[Hb], rTHC) were quantified for 
comparison.  
 The differences of mean values between the presyncope and control groups were 
tested by two-tailed Student t-tests. The time differences of break-points between rMAP 
and each of the other hemodynamic parameters were compared with zero using two-
tailed paired Student t-tests. P-values less than 0.05 are considered significant. All 
average results are presented as mean ± standard deviation (SD). 
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5.3 Results 
5.3.1 Individual Results  
 Figure 5.1 shows illustrative results of MAP and cerebral hemodynamics from a 
control subject (C1 in Table 5.1) without presyncope (Figure 5.1a), and a subject (S1 in 
Table 5.1) with presyncope (Figure 5.1b) and corresponding MSEs of the two-line 
fittings (Figure 5.1c). Sudden changes at the onset of HUT were observed in all measured 
parameters from the two subjects (Figures 5.1a and 5.1b). During HUT, all variables in 
the control subject (C1) were relatively stable (Figure 5.1a). In the control subject, the 
minima of rMAP, rCBF, r[HbO2] and rTHC (C1) were 85%, 68%, 96% and 95% of the 
30-second mean value right after tilt-onset (assigned to be 100%), respectively, and the 
maximum r[Hb] was 129% (Figure 5.1a). By contrast, most parameters measured from 
the presyncope subject (S1) showed relatively larger variations. The rCBF reduction 
during HUT was associated with a decrease in r[HbO2] and an increase in r[Hb]. Since 
[HbO2] accounts for more than 60% of the THC in CBF [154], rTHC primarily followed 
the trend of r[HbO2]. Two stages of physiological responses were observed in the 
measured variables during HUT including slow and gradual changes at Stage I and rapid 
and dramatic changes at Stage II. For each parameter, the break-point between the two 
stages was determined mathematically by the minimum value of MES. However, nadirs 
of MSEs were not always clear in all measured parameters. The maximum changes 
during HUT were observed at Stage II. The minimum value of rCBF (15%) was much 
smaller than those of rMAP (67%), r[HbO2] (65%) and rTHC (94%). The maximum r[Hb] 
was 150%. The onset times of rapid changes in rCBF, r[HbO2], r[Hb], and rTHC at the 
break-points were -3, +231, +320, and +234 seconds relative to that of rMAP, 
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respectively (Figures 5.1b and 5.1c). The positive or negative value of each onset time 
indicated that the rapid and dramatic change of the measured parameter occurred later or 
earlier than that of rMAP (as a zero reference for the comparison). 
 
Figure 5.1 MAP and cerebral hemodynamics from a control subject (a) and a 
presyncope subject (S1) (b), and corresponding MSEs of the two-line linear fittings 
in the subject with presyncope (S1) (c). 
During HUT, all measured variables were relatively stable in the control subject (C1) but 
exhibited two-stage physiological responses in the subject (S1) with presyncope (i.e., 
slow and gradual changes at Stage I, and rapid and dramatic changes at Stage II). The 
solid vertical lines indicate the beginning and ending of tilting up and tilting down. The 
triangles indicate the minima of rMAP, rCBF, r[HbO2] and rTHC, and the maximum of 
r[Hb] during HUT. The two connected dashed lines on top of the raw data (b) 
demonstrate the two-line fitting results. The dashed vertical lines indicate the break-
points separating the Stage I and Stage II. 
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Figure 5.2 MAP and cerebral hemodynamics during HUT (a) and corresponding 
MSEs of the two-line linear fittings (b) in the subject with presyncope (S5). 
All symbols and lines in this figure represent the same meanings as those used in Figure 
5.1. Physiological response trends to HUT in this subject were similar to those shown in 
Figure 5.1 (b) although large variations existed between them in terms of how much and 
how fast these changes were. 
 
Similar trends were observed from all subjects with presyncope although large 
inter-subject variations existed among these subjects. Figure 5.2 shows the data from 
another subject (S5 in Table 5.1) with presyncope. Note that the time scales in horizontal 
axes of Figure 5.1 and Figure 5.2 were not identical due to the different HUT durations. 
Similarly, the minimum value of rCBF (15%) at Stage II was much smaller than those of 
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rMAP (52%), r[HbO2] (80%), and rTHC (92%). The maximum value of r[Hb] was 123%. 
All variables changed slowly before the break-points at Stage I and quickly thereafter at 
Stage II. The onset times of rCBF, r[HbO2], r[Hb], and rTHC at the break-points were -
20, +68, +72, and -4 seconds relative to that of rMAP, respectively. It should be noticed 
that the two stages of dynamic changes were more obvious in rMAP and rCBF than those 
in other variables, and rCBF exhibited greater and earlier decrease at Stage II than other 
parameters in the subjects with presyncope (Figures 5.1 and 5.2). 
 
5.3.2 Average Results 
In the presyncope group, the average time from the beginning of tilting to the 
onset of presyncope was 7.7 ± 5.0 minutes. No significant differences in age, supine 
MAP and HR before tilting were founded between the presyncope and control groups 
(Table 5.2). 
Table 5.2 Average age, supine MAP and HR, and HUT duration 
Average Age, Supine MAP and 
HR, and HUT Duration 
Age (years) 
Supine MAP 
(mm Hg) 
Supine HR 
(BPM) 
HUT 
Duration 
(min) 
Presyncope Group (N = 6) 46.7 ± 14.7 88.4 ± 12.1 64.6 ± 10.0 7.7 ± 5.0 
Control Group (N = 8) 45.6 ± 11.0 82.6 ± 6.5 68.6 ± 6.8 30.0 ± 0.0 
All Groups (N = 14) 46.1 ± 12.2 85.1 ± 9.4 66.9 ± 8.2 20.5 ± 11.8 
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Figure 5.3 Distributions of maximum r[Hb] and minimum rMAP, rCBF, r[HbO2] 
and rTHC in the control and presyncope groups. 
The triangles and circles represent individuals without and with presyncope, respectively. 
The asteroids with error bars represent the group means ± SDs. 
 
Figure 5.3 shows the minimum values of rMAP, rCBF, r[HbO2] and rTHC, and 
maximum values of r[Hb] during HUT measured from the subjects with valid data. 
Compared to control group, presyncope group had significantly lower mean minimum 
values of rMAP (61 ± 19%), rCBF (24 ± 8%), and r[HbO2] (64 ± 12%). However among 
these three parameters (i.e., rMAP, rCBF, r[HbO2]), only the minimum values of rCBF 
exhibited a obvious threshold (~50%) to distinguish all individuals in presyncope group 
(range: 15 to 35%) from those in control group (range: 57 to 85%). There was a time 
interval of 80 ± 79 seconds (range: 14 to 224 seconds) from rCBF reaching the threshold 
of 50% decline to the occurrence of presyncope. Furthermore, there were no significant 
differences in maximum r[Hb] and minimum rTHC between the two groups.   
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Figure 5.4 Onset time differences at the break-points of rCBF, r[HbO2], r[Hb] and 
rTHC relative to rMAP in the presyncope group. 
The asteroids with error bars represent the group means ± standard deviations. The 
dashed horizontal line represents 0 second. The negative/positive value below/above the 
dashed horizontal line (0 second) indicates that the break-point of cerebral hemodynamic 
parameters (i.e., rCBF, r[HbO2], r[Hb] and rTHC) occurred earlier/later than that of 
rMAP. 
 
 Figure 5.4 displays the time differences at the break-points in rCBF, r[HbO2], 
r[Hb], and rTHC relative to rMAP in presyncope group. Only rapid changes of rCBF 
after the break-points occurred consistently earlier (range: 3 to 195 seconds) than those of 
rMAP in all presyncope subjects compared to the other hemodynamic parameters. On 
average, the break-points were observed in the sequence of rCBF (-68 ± 82 seconds), 
rMAP (0 second), rTHC (30 ± 152 seconds), r[HbO2] (53 ± 138 seconds), and r[Hb] (64 
± 192 seconds) when using rMAP as the reference (0 second). However, none of these 
 
90 
time differences at the break-points was significantly different from 0 second (p > 0.05) 
due to the large data variation and small number of subjects. 
 
5.4 Discussion 
Since cerebral hypoperfusion and hypoxia may be the reasons causing the losses 
of consciousness and postural tone during VVS [164, 165], direct and concurrent 
measurement of dynamic changes in CBF and cerebral oxygenation during VVS is 
crucial. A noninvasive device that can simultaneously measure CBF and cerebral 
oxygenation is appealing for predicting VVS. The novel dual-wavelength DCS flow-
oximeter is a portable, rapid, and relatively inexpensive device which offers continuously 
and concurrently measurements of CBF and cerebral oxygenation during on-going tests 
[63, 69, 77, 106, 107]. We reported in the present study the first noninvasive and 
continuous monitoring of both CBF and cerebral oxygenation within the same region of 
brain cortex during VVS using the emerging DCS flow-oximeter.  
Larger variations in MAP and cerebral hemodynamics during HUT were observed 
in subjects with presyncope (Figures 5.1b and 5.2a) compared to the controls without 
presyncope (Figure 5.1a). More specifically, MAP, CBF, [HbO2] and THC decreased and 
[Hb] increased during HUT. These results are consistent with reports from previous 
studies [133, 152, 165, 168, 171].  
We observed two-stage physiological responses during HUT in the presyncope 
group: slow and gradual changes before the break-points at Stage I, and rapid and 
dramatic changes after the break-points at Stage II (Figures 5.1b and 5.2a). Other groups 
also found similar two-stage responses in MAP, CBFV, and [HbO2] during HUT-induced 
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VVS [152, 165-168]. These changes are expected as HUT caused gradual decreases in 
MAP and CBF at Stage I which resulted in gradual decreases in [HbO2] and THC as well 
as a gradual increase in [Hb]. These gradual and slow changes then reached the break-
points leading to Stage II during which physiological autoregulation eventually failed to 
prevent the sharp dynamic changes in the measured parameters. The maximum changes 
of all physiological variables occurred after the break-points at Stage II. Taken together, 
it is anticipated that the abrupt and large physiological changes at Stage II trigged VVS 
eventually.  
Among all the measured variables in subjects with presyncope, rCBF showed the 
largest changes (76 ± 8% decline) at Stage II compared to rMAP (38 ± 19% decline), 
r[HbO2] (36 ± 64% decline), rTHC (18 ± 22% decline), and r[Hb] (22 ± 20% increase) 
(Figure 5.3). This suggests that rCBF is the most sensitive parameter for the evaluation of 
VVS. Similar results were previously found in subjects with VVS induced by HUT [172]; 
percentage maximum drops of mean CBFV (58 ± 14%) in MCA were much larger than 
the decreases in systolic (37 ± 23%) and diastolic (32 ± 20%) blood pressures during 
VVS. In another study, a significant decrease of diastolic CBFV (~ 40%) in MCA of 
subjects with VVS was observed by Schondorf et al [173]. Apparently, the maximum 
rCBF drops (76 ± 8%) in microvasculature shown in the present study were larger than 
the maximum decreases of mean CBFV (58 ± 14%) [172] or diastolic CBFV (~ 40%) 
[173], suggesting that CBF in small vessels may be more sensitive than CBFV in large 
vessels for the evaluation of VVS.  
Moreover, Joo et al found that CBF in the prefrontal cortex measured by SPECT 
during HUT was negatively correlated to the total number of syncopal episodes [174], 
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which had been proven to be the most powerful predictor of a future syncope [175]. 
Therefore, CBF measurement holds potential to assess the recurrence rate of VVS.  
The most important finding in the present study is the threshold of ~50% rCBF 
decline during HUT, which can be used to completely distinguish controls from 
presyncope subjects (Figure 5.3). Potentially, real-time continuous monitoring of CBF 
may provide prognostic information for the occurrence of VVS, i.e., a CBF decrease 
larger than 50% may result in VVS. Although Njemanze also suggested that a ~50% drop 
of mean CBFV in MCA was the critical limit to maintain posture tone and consciousness, 
there were overlaps in their data across the control and VVS groups with this threshold of 
50% CBFV decline [172]. Moreover, the time durations from rCBF reaching this 
threshold to the occurrence of presyncope in the present study were 80 ± 79 seconds 
(range: 14 to 224 seconds). Given the fact that the syncope occurs about two minutes 
after presyncope symptoms [168], detection of the early decrease in rCBF to 50% offers a 
time window of more than 2 minutes for predicting/preventing VVS.    
Our study found that rCBF reached the break-point earlier (Figure 5.4) than other 
measured variables, although the time differences at break-points were not statistically 
significant. For example, the break-point of rCBF exhibited at 68 ± 82 seconds (range: 3 
to 195 seconds) before rMAP. The insignificance may attribute to the small number of 
subjects and large variations in time differences (i.e., 68 ± 82 seconds). Nevertheless, our 
findings are consistent with the results documented by Dan et al where the CBFV drops 
were found to significantly lead the MAP declines by 67 seconds (range: 9 to 197 
seconds) [166]. The earlier changes in CBF or CBFV compared to other physiological 
variables imply that the cerebral hypoperfusion at Stage II after the break-point may be 
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the primary trigger resulting in rapid changes in other physiological parameters. It is 
known that the right insular cortex is responsible for regulating sympathetic activities 
such as blood pressure and heart rate [171, 174, 176]. Reduced CBF in the right insular 
cortex may possibly suppress sympathetic activities, eventually triggering VVS [174].  
As expected, cerebral hypoperfusion (i.e., CBF reduction) occurred during 
presyncope along with cerebral hypoxia (i.e., [HbO2] decrease and [Hb] increase).  
Among all measured cerebral oxygenation parameters, only the minimum values of 
r[HbO2] during HUT exhibited significant differences between the control and 
presyncope groups (86 ± 13% versus 64 ± 12%, p = 0.020, see Figure 5.3). This may be 
due to the relatively larger changes in [HbO2] (compared to [Hb] and THC) during VVS 
observed in our study and from previous investigations [152, 168]. In addition, due to the 
relatively smaller changes in r[HbO2], r[Hb] and rTHC compared to other measured 
variables (i.e., rMAP and rCBF) their break-points were not always clear during 
presyncope (Figure 5.2a). This led to large variations in time differences between 
cerebral oxygenation variables and MAP determined at the break-points (Figure 5.4), and 
possibly resulted in evaluation errors. 
 
5.5 Conclusions 
This study focuses on testing the feasibility of the novel dual-wavelength DCS 
flow-oximeter in detecting physiological responses during VVS. All measured 
physiological parameters were fairly stable during HUT in control subjects without 
presyncope. By contrast, subjects with presyncope exhibited two stage responses: slow 
and gradual changes at Stage I before the break-points and rapid and dramatic changes at 
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Stage II after the break-points. Among all measured variables, rCBF had the largest 
decrease and reached the break-point at earliest time at Stage II, implying the best 
sensitivity of rCBF for the evaluation of VVS. Most importantly, a threshold of ~50% 
rCBF decrease determined from this study can be potentially used to predict the 
occurrence of VVS. Ultimately, such information may be used to warn subjects at high 
risk for the recurrence of VVS, or even avoid VVS via an automatic feedback (e.g., an 
anti-gravity suit used for an Air Force pilot) for keeping cerebral hemodynamics in a 
normal level.   
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CHAPTER 6 STUDY SUMMARY, LIMITATIONS, AND FUTURE 
PERSPECTIVES 
6.1 Study Summary 
In this dissertation, I described the development of various NIR diffuse optical 
instruments for cerebral hemodynamic measurements including a fast DCS flowmeter 
with an autocorrelator working in burst mode, an upgraded hybrid NIRS/DCS device 
integrating a commercial tissue-oximeter (Imagent) and a custom-made DCS flowmeter, 
and a custom-designed dual-wavelength DCS flow-oximeter. I also reported clinical 
applications of these techniques in quantification of cerebral hemodynamics and CA. 
More specifically, I explored to evaluate dynamic CAs in both time-domain and 
frequency-domain via simultaneous measurements of CBF, cerebral oxygenation, and 
MAP. The results reported in this dissertation have been presented in 
local/regional/national/international conferences and some of them have been published 
or submitted to peer-reviewed journals [25, 113, 177] (see attached CV). 
My major contributions in these studies include the following aspects. I have 
designed, constructed, and tested an upgraded new generation hybrid NIRS/DCS device 
(Chapter 2), which can measure CBF and cerebral oxygenation simultaneously, providing 
critical information for evaluation of cerebral hemodynamics and CA. In the upgraded 
hybrid device, I adopted a new autocorrelator board working in burst mode, which 
dramatically increased DCS sampling rate. High sampling rate is necessary to capture 
instantaneous changes in cerebral hemodynamics (e.g., LFO signals) for evaluation of 
dynamic CA. I wrote the control program for the upgraded hybrid NIRS/DCS instrument 
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using Microsoft Visual Basic, which automatically controlled data collection and storage 
as well as the communication between the two devices. ABP waveform outputs from the 
finger plethysmograph were also recorded by our instrument (Chapter 4). I have also 
participated in the development of a novel portable dual-wavelength DCS flow-oximeter 
which can simultaneously measure relative changes of CBF and cerebral oxygenation 
(Chapter 2). I also designed several detector fiber bundles for spatially averaging DCS 
signals, which significantly improved the SNR of DCS measurements (Chapters 4 and 5).  
In terms of clinical studies, I recruited research subjects, designed experimental 
protocols, implemented data collections, and created the methods for data analysis 
(Chapters 3, 4 and 5). The general methods of data analysis in these studies were 
implemented in Matlab (Chapters 3, 4, and 5). In Chapter 3, I reported our first attempt to 
evaluate dynamic CA in cerebral microvasculature in patients with OSA. In Chapter 4, I 
reported the first successful detection of LFOs in both CBF and cerebral oxygenation. In 
this study, I have determined the best hemodynamic parameters (i.e., CBF, [HbO2] and 
THC) among our measured variables and optimal physiological condition (HUT) in 
detecting LFOs for the quantification of LFO phase shifts. We expected that direct and 
simultaneous measurements of LFOs in CBF and cerebral oxygenation will bring new 
insights about CA mechanisms and pathologies of cerebral diseases. In Chapter 5, I 
reported, for the first time, the simultaneous monitoring of CBF and cerebral oxygenation 
during VVS. Our results suggest that CBF has the best sensitivity for the assessment of 
VVS and is likely the final trigger of VVS. Most importantly, a threshold of ~50% rCBF 
decline is determined which can completely separate the subjects with or without 
presyncope, suggesting its potential for predicting VVS.  
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6.2 Study Limitations and Future Perspectives  
Technical limitations and improvements. The uses of 2.5 cm S-D separation in 
the present studies for DCS measurements [38, 50, 63, 64, 148] (Chapters 3, 4, and 5) and 
3 cm S-D separation for NIRS measurements (Chapter 4) have been demonstrated 
previously in various human studies. Also, Monte Carlo simulations of NIR light paths in 
human brain have shown that the 2.5 cm and 3 cm S-D separations are sufficient to detect 
tissue hemodynamics in prefrontal cortex [178]. However, there are always some 
contributions to the cortex signals from the overlaying tissues (e.g., skin and skull), i.e., 
the partial volume effect [112, 179]. In the future, multiple S-D separations and multi-
layer theoretical models [180] should be used to precisely quantify cerebral 
hemodynamics.  
The ~2 Hz sampling rate by adopting the burst mode and the spatial averaging 
method used in our study provided adequate SNRs to capture fast dynamic changes in 
cerebral hemodynamics. However, a faster sampling rate is always appealing as it can 
reduce measurement errors in detection of rapid hemodynamic changes (e.g., after an 
autoregulation stimulus and during VVS) as well as diminish the low frequency alias 
(e.g., cardiac frequency at ~ 1Hz), which may contaminate LFO signals. Several methods 
may be attempted in the future to improve data acquisition rate while maintain SNRs 
including using a faster autocorrelator, spatial averaging signals from more detection 
channels, and adopting few-mode fibers to replace the currently used single-mode fibers 
[108].  
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Currently, The DCS/NIRS instruments need off-line data analysis. Online and 
continuous reporting of hemodynamic results is critical for clinical applications. For 
example, the predication and prevention of VVS should be done in real time. In addition, 
current control software requires manual inputs of instrument configuration for different 
experiments, which is difficult for beginners. An easy-to-use control panel should be 
developed to enable automatic loading of instrument settings for different applications. 
Experimental/clinical limitations and improvements. Physiological 
manipulations used in our studies either created relatively small hemodynamic variations 
(i.e., bilateral thigh pressure cuff occlusion) or may result in VVS (i.e., HUT). Other 
manipulations should be explored in the future to create relative large cerebral 
hemodynamic perturbations without causing syncope.  
Although we used both TD and FD methods to quantify dynamic CA, the 
sensitivities of the two methods in evaluating CA have not been directly compared yet. 
Future study will assess both TD and FD dynamic CAs in the same subject population to 
evaluate and optimize the approaches for the assessment of dynamic CA.  
CBF is also sensitive to changes in arterial carbon dioxide (CO2) content via 
changes in respiration. Therefore, investigation of cerebral hemodynamics and CA should 
also include the assessment of CO2 levels (e.g., End Tidal CO2) and respiratory rate [181], 
which will be the subject of future work.  
The numbers of subjects reported in this dissertation are small. More subjects will 
be recruited to improve the statistic power of our study. Future study should also include 
more patient populations (e.g., stroke, carotid artery stenosis, orthostatic hypotension) to 
test the capability of our novel techniques in diagnosis of cerebral vascular diseases.  
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It is expected that with further technical development/improvement and more 
clinical applications in large patient populations, the NIRS/DCS techniques described in 
this dissertation might emerge as important tools for the diagnosis of cerebral vascular 
diseases and management of therapies at the bedside of clinic. 
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APPENDIX: GLOSSARY 
SYMBOLS 
α   Ratio of Dynamic to Static Scatterers (0 - 1) 
ac   Modulated Light Amplitude 
C   Hemoglobin Concentration of Whole Blood 
γ   Percentage of Blood Volume Contained in the Venous Compartment 
D   Photon Diffusion Constant 
Db   Effective Diffusion Coefficient 
DC  Average Light Intensity 
AC  Peak-to-peak Light Intensity 
g1   Normalized Electric Field Temporal Autocorrelation Function 
G1   Unnormalized Electric Field Temporal Autocorrelation Function 
g2   Normalized Intensity Temporal Autocorrelation Function 
I   Intensity 
k0   Wavevector of Photons in Medium (k0 = 2π /λ 
λ   Wavelength 
n   Ratio of Sample and Air Index of Refraction 
φ   Phase Shift Between the Detected and Source NIR Light  
r   Position Vector  
ρ   Source-detector Separation 
<Δr
2
(τ) >  Mean square displacement q D S τ 
SAC   Slope of ρ vs. AC component light intensity Curve 
SDC   Slope of ρ vs. DC component light intensity Curve 
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Sφ   Slope of ρ vs. Phase shift Curve 
S0   Source-light Distribution 
τ   Correlation Function Decay Time 
μa   Absorption Coefficient 
μs’   Reduced Scattering Coefficient 
v   Speed of Light in Medium 
ω   Angular Frequency of Modulation 
 
TERMS 
[Hb]  deoxygenated hemoglobin concentration (unit μM) 
[HbO2] oxygenated hemoglobin concentration (unit μM) 
Δ[Hb]  deoxygenated hemoglobin concentration change (unit μM) 
Δ[HbO2] oxygenated hemoglobin concentration change (unit μM) 
ΔTHC  total hemoglobin concentration change (unit μM) 
r[Hb]  relative deoxygenated hemoglobin concentration change (unit %) 
r[HbO2] relative oxygenated hemoglobin concentration change (unit %) 
rCBF  relative cerebral blood flow change (unit %) 
rMAP  relative mean arterial pressure change (unit %) 
rTHC  relative total hemoglobin concentration (unit %) 
ABP  Arterial Blood Pressure 
APD   Avalanche Photodiode 
ASL-MRI  Arterial Spin-Labeled Magnetic Resonance Imaging (Perfusion MRI) 
BFI   Blood Flow Index (αDB) 
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BOLD-MRI Blood Oxygen Level Dependent Magnetic Resonance Imaging 
BPM  Beat per Minute 
CA  Cerebral autoregulation 
CBF   Cerebral Blood Flow 
Coh  Coherence 
CW   Continuous Wave 
CT  Computed Tomography 
DCS   Diffuse Correlation Spectroscopy 
DAP  Diastolic Arterial Pressure 
DLS   Dynamic Light Scattering 
DWS   Diffusing Wave Spectroscopy 
EtCO2  End-tidal CO2 
FD   Frequency-Domain 
Hb   Deoxy-hemoglobin 
HbO2   Oxy-hemoglobin 
HUT  Head-up Tilting 
LFO  Low Frequency Oscillation 
MAP  Mean Arterial Blood Pressure 
MCA  Middle Cerebral Artery 
NIR   Near-Infrared 
NIRS   Near-Infrared Spectroscopy 
OSA  Obstructive Sleep Apnea 
PET   Positron Emission Tomography 
 
103 
PMT   Photomultiplier Tube 
PSD  Power Spectrum Density 
SBP  Systolic Blood Pressure 
SNR   Signal to Noise Ratio 
StO2   Tissue Blood Oxygen Saturation 
TCD  Transcranial Doppler  
TD   Time-Domain 
TFA  Transfer Function Analysis 
THC   Total Hemoglobin Concentration 
VVS   Vasovagal Syncope 
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